Nanomaterial-Based Electrochemical Nanodiagnostics for Human and Gut Metabolites Diagnostics: Recent Advances and Challenges

Amit K. Yadav 1,†, Damini Verma 1,†, Reena K. Sajwan 1, Mrinal Poddar 1,©, Sumit K. Yadav 2, Awadhesh Kumar Verma 1 and Pratima R. Solanki 1,*

1 Nano-Bio Laboratory, Special Centre for Nanoscience, Jawaharlal Nehru University, New Delhi 110067, India
2 Department of Biotechnology, Visva-Bharati University, Hazaribagh 825301, India
* Correspondence: pratimarsolanki@gmail.com or partima@mail.jnu.ac.in;
Tel.: +011-26704740 or +011-26704699
† These authors contributed equally to this work.

Abstract: Metabolites are the intermediary products of metabolic processes catalyzed by numerous enzymes found inside the cells. Detecting clinically relevant metabolites is important to understand their physiological and biological functions along with the evolving medical diagnostics. Rapid advances in detecting the tiny metabolites such as biomarkers that signify disease hallmarks have an immense need for high-performance identifying techniques. Low concentrations are found in biological fluids because the metabolites are difficult to dissolve in an aqueous medium. Therefore, the selective and sensitive study of metabolites as biomarkers in biological fluids is problematic. The different non-electrochemical and conventional methods need a long time of analysis, long sampling, high maintenance costs, and costly instrumentation. Hence, employing electrochemical techniques in clinical examination could efficiently meet the requirements of fully automated, inexpensive, specific, and quick means of biomarker detection. The electrochemical methods are broadly utilized in several emerging and established technologies, and electrochemical biosensors are employed to detect different metabolites. This review describes the advancement in electrochemical sensors developed for clinically associated human metabolites, including glucose, lactose, uric acid, urea, cholesterol, etc., and gut metabolites such as TMAO, TMA, and indole derivatives. Different sensing techniques are evaluated for their potential to achieve relevant degrees of multiplexing, specificity, and sensitivity limits. Moreover, we have also focused on the opportunities and remaining challenges for integrating the electrochemical sensor into the point-of-care (POC) devices.

Keywords: biosensors; biomarkers; diagnosis; metabolites; nanomaterials

1. Introduction

Nutrition conversion, which comprises a transformation from consumption of conventional to modern foods containing low nutrient diversity and high-energy density, is linked to the developed metabolic syndromes. The human diet is the composition of various elements containing non-nutrients and nutrients, providing the raw materials and driving several metabolic reactions in every body cell [1,2]. These elements and their metabolites also regulate the gene expression and functioning of cellular activities through different mechanisms. Among all the components, some of them show positive and negative effects. Researchers have studied that constant interruption in energy homeostasis or/and nutrient metabolism may occur due to the excess or deficiency of nutrients, which initiate cellular stress and lead to tissue damage and metabolic deregulations, and ultimately result in the development of metabolic syndromes [3–5]. Presently, it is evident that metabolism is affected by external reasons such as environment and food; internal reasons such as gene variations, gender, and age; and microbiota contact, that jointly mutate the threat of...
developing acquired metabolic sicknesses and various health issues in humans as shown in Figure 1. The gut microbiota has recently gained attention as it has affected human health significantly by living inside the human intestine. Accumulating evidence suggests that under normal circumstances, the gut microbiota has played a fundamental role in maintaining good human health in various aspects and also maintaining a mutualistic symbiotic relationship in which both benefit one another (eubiosis) [6,7]. Either way, the change in gut microbiota composition has shown an association with human diseases, which remains a critical area of investigation for many researchers. Various metabolites are being produced by gut microbiota from nutrients of dietary sources such as trimethylamine N-oxide (TMAO), trimethyl-amine (TMA), indole derivatives, nicotinamide, and short-chain fatty acids (SCFAs), that contribute to human diseases substantially, such as metabolic diseases and cardiovascular diseases [8,9], cancer and inflammation [10], depression [11], and colorectal cancer [12]. Some metabolites generated from the gut microbiome, including butyrate, propionate, and SCFAs such as acetate, have shown critical roles in human health and are considerably associated with kidney diseases, hypertension, and inflammatory bowel diseases [13,14]. The research in the field of gut metabolite advises that these could be used as a prognostic and diagnostic marker for numerous human diseases such as diabetes, cardiovascular, colorectal cancer (CRC), etc. [15]. The fast and cost-effective diagnosis of gut disease at the earliest stage raises challenges for patients, health institutions, and governments for efficient clinical results. It is also becoming clear that consuming diets rich in nutrient diversity and low in energy density may enhance and maintain good health.

Moreover, the measurement of metabolites has gained growing interest in clinical research. Metabolites are hardly soluble in an aqueous medium; as a result of this, the concentration of the metabolite in biological fluids is deficient. Therefore, a selective and sensitive determination of metabolites is challenging to measure with existing techniques in biological samples. Various conventional and non-electrochemical techniques such as chromatography, raman spectroscopy, surface-enhanced raman scattering (SERS) spectroscopy, and electrochemistry have been developed to analyze metabolites in biological samples [16]. SERS is a viable technology to recognize biological and chemical components through their distinct vibrational fingerprints. It opens a new way for biomedical analysis, such as point-of-care analysis, precision component-based imaging, biomolecular detection, and cancer diagnostics. SERS biosensing at the molecular level has been limited by noble metals and fixed probes [17,18]. High-performance liquid chromatography (HPLC) is a widely utilized method for metabolites detection. In HPLC, sample preparation and extraction are very important steps before the measurement occurs. Solid phase extraction (SPE) and solid phase microextraction (SPME) are conventional solvent-free pre-treatment methods associated with the HPLC. Apart from the solvent-free process, the preparation and selection of appropriate SPE and SPME sorbent are essential as they can drastically influence the ability and selectivity of sample extraction [19]. Although these methods are highly sensitive, they have the disadvantages that they are complex, time consuming, costly, and dependent on complicated instrumental setups and skilled manpower, due to which these techniques are not practical in routine measurement [20,21].

In contrast, the electrochemical techniques are more suitable for the selective determination of biomarkers. These methods are highly sensitive, cost-effective, affordable, fast, and have a simple design. Over the past years, the need has arisen in medical diagnostics fields for disposable and simple devices displaying suitable, cost-effective, user-friendly, and fast response times for mass fabrication [22–24]. Biosensor technologies have provided the potential to achieve the above conditions via an interdisciplinary mixture of medical science, chemistry, and nanotechnology techniques. The various advantages of biosensors are high precision, low cost, and rapid analysis applied in numerous fields, such as the fermentation industry, environmental monitoring, antibiotics detection [25–27], disease diagnosis [28–30], and medical care [31]. Biosensing technology provides significant advantages over traditional detection methods such as spectroscopy or chromatography. These advantages include reduced demand for qualified individuals, faster response time,
mobility, and enhanced sensitivity. Because of the rising demand for controlling the target molecules in the human body and the environment, nanomaterials have recently sparked a lot of attention. Nanomaterials are materials with at least one dimension of 1–100 nm. Controlled tuning and synthesis of nanomaterial characteristics need data of several disciplines, including agriculture, engineering, biology, computer science, electronics, chemistry, physics, and so on, which may result in the birth of unique and multifunctional nanotechnologies. In this context, nanomaterials’ fascinating characteristics have piqued the scientific community’s interest in their use in various fields including security, food, health, information technology, and transportation, among others. It is anticipated that the intelligent usage of nanomaterials would improve the biomolecular electrical devices’ performance with high detection limitations and sensitivities.

This review will acquaint the reader with recent research articles on the importance of human and gut microbiome-derived metabolites in developing disease and human health. Moreover, it highlights the current advancement and newly reported electrochemical methods that can be designed to investigate clinically appropriate human and gut metabolites for onset determination and screening of the progress of particular diseases. This is a broad and fast-growing field, and this review presents the collective and important information gathered from the past five years of research to help the researchers select appropriate biomarkers for their upcoming analysis. The current review also summarized

**Figure 1.** Factors that influence human health, extrinsic and intrinsic factors. The interaction between the host-microbiota that jointly modify the energy and nutrient metabolism, program of gene expression, and biological processes results in various health issues in humans [Adapted with permission from ref. [32]. Copyright 2015 Springer].

This review will acquaint the reader with recent research articles on the importance of human and gut microbiome-derived metabolites in developing disease and human health. Moreover, it highlights the current advancement and newly reported electrochemical methods that can be designed to investigate clinically appropriate human and gut metabolites for onset determination and screening of the progress of particular diseases. This is a broad and fast-growing field, and this review presents the collective and important information gathered from the past five years of research to help the researchers select appropriate biomarkers for their upcoming analysis. The current review also summarized
the overviews of various sensors and their performance metrics, such as limit of detection (LOD) and dynamic range. We further highlighted the current boundaries in the biosensing field and their future encounters.

2. Nanomaterial-Based Biosensors for Metabolites Detection

For the determination of clinically relevant metabolites, it is crucial to understand the fundamentals of their physiological and biological functions and clinical diagnostics [33]. These molecules are associated with various biological processes, such as catalyzing and regulating biological activities, transporting small molecules, and transmitting and storing genetic information. In addition to that, they can be used as an important biomarker that helps in the reorganization and diagnosis of several diseases. Medical investigation is no longer made in clinical test centers [34]. As an alternative, it is regularly performed at numerous units, such as the hospital point-of-care unit, nonhospital take-care unit, and home [35]. The electrochemical determination methods are suitable for rapid and on-the-spot application [36]. These methods can potentially develop selective, affordable, rapid, and sensitive systems for determining various analytes, which are important for clinical diagnosis and monitoring disease treatment [37]. The electrochemical nanobiosensors have been developed by using nanomaterials in which nanomaterials act as an electrode. In electrochemical biosensors, an electrode converts a response signal into an electrical signal generated from biomolecules that act as receptors when binding to the target molecules [38,39]. In the next section of this review, we include several ways used for small molecules and ions to selectively detect (1) specific biorecognition elements such as ionophores, double-stranded nucleic acids, DNAzymes, affinity ligands, whole cells, coenzymes, enzyme-mimicking metalloproteins, enzymes, aptamers, antibodies biological receptors, and molecular imprinted polymers (MIPs) which act as artificial receptors; (2) the use of electrocatalytic electrode-coating and conducting films which improve the electrochemical signal response interference of other analytes, (3) nanostructure interfaces which reduce the signal-to-noise ratio and improve the sensitivity of a sensor, and (4) chemometrics which eradicate the signal overlapping with the interfering analytes and other small molecules. The analytical performance of the biosensor could be enhanced by implementing these approaches while constructing the sensors.

Further, the biosensor technique has improved the growth of nanoscience and nanotechnology. The capability to alter and control the materials at an atomic level, i.e., nanometre scale, and consequently understand its basic process at the nanoscale led to innovative biosensor development. Nanomaterials (NMs) are generally categorized on the basis of their dimensions such as zero-dimensional (0D), first (1D), second (2D), and third (3D) nanomaterials. The dimensions of the nanomaterials play an essential role in determining their physical, chemical, biological, electrical, and optical properties [36]. With advancements in nanotechnology, research and development (R&D) in biosensors has emerged as a multidisciplinary and open field. Nanotechnology breakthroughs have accelerated the development of medical diagnostic assays and devices that are quicker, economical, highly sensitive, and much more accurate. Nanomaterial-based biosensors combine diverse fields such as chemistry, molecular engineering, material science, and biotechnology. They have such great sensitivity that specific biosensors can potentially detect as little as one parasite per microlitre of blood. Nanotechnology combined with genomics, proteomics, and molecular machinery can contribute to the creation of efficient, dependable, and quick onsite medical diagnostics. Nanotechnology has transformed these techniques by facilitating the fabrication of innovative materials for developing medical diagnostic instruments. Using nanoscience to regulate, manage, and integrate atoms and molecules to construct nano-dimensional (1–100 nm) structures and components open up new avenues for diagnostic-device development. Because of their tiny structures and high surface area to volume ratio, they have precious properties. By exploring different NMs, such as nanocomposites (dendrimers), quantum dots (QDs), nano-wires, nano rods, carbon nanotubes (CNTs), graphene dots, and nanoparticles (NPs) (metal and metal oxide-based)
with distinct characteristics offers the chance to improve the performance of the biosensor and LOD by controlling the morphology and size of NMs [40,41].

2.1. Biosensors for Human Metabolites Detection

In metabolism, the intermediate and final products are the metabolites. These metabolites can be glucose, urea, uric acid, lactates, cholesterol, creatine, hydrogen peroxide, ketone bodies, creatinine, hypoxanthine, xanthine, etc. There have been some significant breakthroughs via electrochemical sensors in clinical applications concerning one of the major constituents, glucose. The economic and sturdy nature of commercially available electrochemical glucometers is a strong indicator of their success. Here we will discuss some of the significant developments of biosensors in different metabolites as summarized in Table 1.

2.1.1. Glucose

Diabetes mellitus is recognized as a global-wide health issue. This kind of metabolic disorder is due to insulin insufficiency in the blood and is related to fluctuations in blood glucose concentrations in the optimum range (4.4–6.6 mM) [42]. Initially, the commercially available glucose sensors had glucose oxidase enzyme immobilized over an electrode surface. Moderators were used at the surface of the electrode interface and enzyme for enhanced electron transport [43]. In the third generation of glucose sensors, direct electron transfer was instigated at the interface [44]. These sensors had outstanding specificity, although there were issues related to denaturation of the enzyme and reduced reproducibility after storage [45]. The non-enzymatic glucose sensors can be used as an alternative to overcome these shortcomings. However, they work in an alkaline environment unsuitable for in vivo applications.

Recently, different analytes have been utilized instead of blood for glucose monitoring, such as an enzymatic amperometric sensor that detects glucose fluctuations in tears [46]. The sensor was based on glucose oxidase immobilization over the electrode surface (iridium/platinum wire of 0.25 mm) and the release of hydrogen peroxide (H$_2$O$_2$) caused by the enzymatic reaction was detected at the anode, as shown in Figure 2iv. To reduce the interferent intrusion and enhance specificity in tear fluids, nafion and an electro-polymerized film of 1,3-diaminobenzene/resorcinol have been used as inner layers. The limit of detection (LOD) of the glucose sensor was 1.5 µM with a sample volume of just 4–5 µL.

For detection of glucose fluctuations in different biological fluids such as urine, serum, and blood, a microfluidic paper-based electrochemical device (µPED) was fabricated. The µPED consists of microfluidic channel patterns made through wax-printing or photolithography and screen-printed electrodes (SPE) utilizing conducting inks (such as Ag/AgCl or carbon) over the paper surface [47] [Figure 2iii]. Glucose oxidase was set over the paper microchannel. Through chronoamperometry (CA), a linear calibration was made for glucose levels up to 22.2 mM. A different type of paper-based sensor was fabricated for conducting a flow-injection glucose study [48]. In this system, the buffer solution from the elevated reservoir moves to the sink below through gravity-driven capillary transport. The nitrocellulose membrane was utilized as an intermediate for glucose oxidase immobilization over a thin platinum electrode fixed over a rigid surface. The reference and counter electrodes were set in an elevated reservoir. CA made it possible for glucose monitoring of up to 26 mM, with 0.2 mM LOD as shown in Figure 2ii. This technique is independent of throwaway test strips.

Solanki et al. have used polyvinyl alcohol capped copper oxide (PVA-CuO) NPs to fabricate novel capacitive biosensors to detect glucose concentrations non-enzymatically [49]. The designed nano biosensor showed a decline in capacitance measurements with increasing glucose concentration. Further, a highly specific capacitive sensor based on the thin film of PVA-CuO over ITO using ARDUINO UNO has been developed by Solanki et al. for non-enzymatic detection of glucose [50]. The obtained studies showed a decline in capacitance measurements with increasing glucose concentrations. The reproducibility and
repeatability of the developed system were five chips and six readings, respectively, with a shelf-life of 4 weeks. Moreover, Solanki et al. fabricated novel biosensing platforms for immobilizing GOx over gelatin B [47] and agar [48] ionogels-modified ITO electrodes to detect glucose concentration. Both ionogels have been made in ionic liquid solutions such as 1-octyl-3-methyl imidazolium chloride and 1-ethyl-3-methylimidazolium chloride. The gelatin B ionogels-based bioelectrodes displayed a detection range from 1–20 mM, LOD of ≈ 0.174 mM having a sensitivity of 4.6 μA mM⁻¹ cm⁻². The agar-ionogels-modified ITO electrodes (GOx/Ag–C2/ITO and GOx/Ag–C8/ITO) showed improved sensitivity of 14.6 μA mM⁻¹ cm⁻² and ≈4.1 μA mM⁻¹ cm⁻² with a linear range of 0.28–5.6 mM and 0.27–16.7 mM, respectively.

A worldwide mobile electrochemical detector (μMED) was fabricated to utilize in different applications with few resources [51]. This device can be operated with a wide variety of electrode types which can be connected to the Internet using any smartphone [Figure 2i]. The μMED had glucose oxidase-modified test strips for directly sensing glucose in the blood. CA was utilized to measure glucose from 2.8 to 27.8 mM in a linear range. Direct integration of the sensing platform over glucose renewable sensor strips has been performed using a roller pen with enzyme-based ink [52]. This enzyme-based ink pen allowed a simplistic facile creation of excellent economic amperometric sensors with a malleable design for different surfaces. The renewable sensor strips show excellent repeatability of up to 20 cycles of 2 mM glucose with constant high sensitivity in blood.

Figure 2. (i) Image showing μMED interfaced with a cellular device and commercial glucose test strip for data transmission over voice via an audio cable [Adapted with permission from ref. [52], Copyright 2014 National Academy of Sciences of the United States of America]; (ii) Schematic representation of the electrochemical detection of glucose in a paper-based flow system [Adapted with permission from ref. [48], Copyright 2012 ACS]; (iii) Scheme depicting the development of amperometric glucose biosensor for quantification of glucose levels in tears [Adapted with permission from ref. [47], Copyright 2011 ACS]; and (iv) Scheme depicting a paper-based electrochemical sensing device for glucose detection [Adapted with permission from ref. [46], Copyright 2010 RSC].
The plant lectin Concanavalin A (Con A) has been the focus of considerable research efforts to fabricate affinity-based glucose sensors because of its intrinsic activity and stability under physiological pH [47,53]. For example, gold nanoparticles (GNPs) coated with Con A were constructed on a gold electrode with polytyramine modification to create a competitive capacitive glucose sensor [54]. The biosensor showed a linear response to concentrations of glucose ranging from 1 µM–10 mM under optimum parameters according to the results. Another non-enzymatic glucose sensor was developed with localized pH modulation within a symmetric Au–Au junction electrode [55]. This study made a paired Au–Au joint electrode by electro-depositing gold onto two platinum disc electrodes kept close together. To elevate the pH locally, the working electrode’s potential was fixed to 1.5 V against the saturated calomel electrode (SCE). The sensor response was linear within the physiological glucose range of 1–10 mM, according to CV and SWV measurements.

Moreover, Bansi D Malhotra, also known as the father of Indian biosensors, has contributed significantly to the development of glucose biosensors using various types of nanomaterials. Malhotra and his co-workers proposed an enzymatic glucose sensor utilizing glucose oxidase (Gox) attached onto sol–gel derived CeO$_2$–TiO$_2$ nanocomposite that was electrophoretically deposited onto an ITO electrode [56]. The sensor showed a wide linearity (0.56–22.2 mM) and a sensitivity of 53.48 µA mM$^{-1}$ cm$^{-2}$ with a LOD of 10 mg dL$^{-1}$. Further, nano-structured polyaniline (NS-PANI) has been electrophoretically deposited over ITO to immobilize Gox to design a glucose biosensor by Malhotra et al. The developed biosensor displayed excellent sensitivity of 1.05 × 10$^{-4}$ mA mg$^{-1}$ dL$^{-1}$, linear range up to 400 mg dL$^{-1}$ having a LOD of 2.1 mM [57]. Further, Malhotra et al. developed a glucose sensor using Gox immobilized over thin films of cerium oxide (CeO$_2$) NPs deposited onto platinum (Pt) coated glass plate using pulsed laser deposition (PLD) [58]. The Gox/CeO$_2$/Pt biosensing platform showed a wide detection range of 25–300 mg dL$^{-1}$ towards measuring glucose concentration with a LOD of 1.01 mM.

Recently, several nanocomposite-based biosensors have been reported for glucose detection using Cu/Cu$_2$O/NiO hybrid for serums and beverages [59], wearable glucose determination in interstitial fluid of rats [60], and MXenes (Ti$_3$C$_2$T$_x$)-based nanocomposites with Cu$_2$O [61].

2.1.2. Lactose and Galactose

Lactose is a disaccharide broken down into monosaccharides, glucose, and galactose, via the lactase enzyme within the gastric tract. Lactose levels in the blood can be used to determine whether or not a patient has gastrointestinal cancer [62].

An enzyme-based lactose amperometric sensor was fabricated by immobilization of β-galactosidase enzyme in the stratified film of poly(vinylsulfonate) and poly(ethyleneimine), as shown in Figure 3i. The film was deposited over a Prussian blue-covered ITO electrode [63]. This sensor led to a linear detection for lactose concentrations and had 1.1 mM as LOD. The other lactose-specific enzyme, i.e., cellobiose dehydrogenase, was used to develop an amperometric-based lactose sensor [64]. The enzyme was made to attach with MWCNTs and poly(3-amino-4-methoxybenzoic acid-co-aniline) nanohybrid followed by its deposition on a gold electrode surface. The sensor achieved linearity for lactose concentrations up to 30 mM [Figure 3ii]. Further, a lactose biosensor based on Langmuir–Blodgett (LB) films of poly(3-hexyl thiophene) (P3HT)/stearic acid (SA) has been fabricated by Malhotra et al. by immobilizing lactase and galactose oxidase (GaO) for quantification of lactose in milk and its products. The bioelectrodes showed linearity of 1–6 g dL$^{-1}$ with a shelf life of more than 120 days [65].

A galactose amperometric biosensor was developed by Malhotra et al. using monoenzyme GaO for the detection of galactose in milk and milk products [66]. The P3HT/SA was used to immobilize GaO on an ITO-covered glass substrate utilizing Langmuir–Blodgett (LB) film deposition approach. The fabricated enzyme biosensor showed a linear detection range of 1–4 g dL$^{-1}$ galactose. In another work, Malhotra et al. proposed an enzyme biosensor for the determination of galactose in human serum by Malhotra et al. [67].
Monolayers of poly(3-hexyl thiophene) were formed by dispensing a mixed solution of stearic acid in chloroform. The fabricated galactose biosensor presented a linear response in blood serum from 0.05–0.5 g galactose L\(^{-1}\). Moreover, some recently developed biosensors are also reported for electrochemical detection of lactose [68,69].

2.1.3. Uric Acid (UA)s

Uric acid, i.e., UA, is the most abundant nitrogenous element present in urine that is linked to several medical conditions. Other pathological and gout problems such as kidney, diabetes, heart disease, high blood pressure, and obesity may be caused by an increased UA concentration in the blood, commonly known as Lesch–Nyhan syndrome or hyperuricemia. UA concentrations in the blood should be between 200 and 400 \(\mu\)M [70]. The intrusion generated by other biomolecules with similar oxidation potentials, such as ascorbic acid, is one of UA’s most significant issues with direct biological measurement [71].

An amperometric enzymatic-based biosensor for UA was developed with a glassy carbon electrode (GCE) with Nafion film and ferrocene-induced electro-activated uricase enzyme deposited inside [72]. Uricase electro-activation was attained by the CV arising from the electrostatic interaction between the tryptophan and Fc molecules that remain inside the enzyme’s hydrophobic pockets. This biosensor had a linearity (500 nM to 600 \(\mu\)M) with a 230 nM detection limit. Using boron-doped diamond (BDD) microelectrodes, a non-enzymatic test for UA in urine was devised, as shown in Figure 3iii [73]. BDD’s outstanding features, such as low non-specific adsorption of other species, minimal background current, antifouling characteristics, and excellent stability after electrochemical reactivation, are only a few advantages used to support the strategy. When ascorbic acid is present, its direct determination of UA values down to 1 mM was possible. In a similar method, a gold electrode coated with sulfur-adlayer was fabricated for UA detection. The sensor aided oxidation of UA at a considerably low overpotential with an increased current density with reference to an unmodified electrode [74]. This electrochemical sensor showed linearity for UA between 2.5 \(\mu\)M to 5 mM, having a detection limit of 0.4 \(\mu\)M. A sensor modification with dendrimer was fabricated for specific detection of UA when ascorbic acid is present [75]. In this sensor, a GCE was consecutively changed with poly(amidoamine) (PAMAM) dendrimers containing 128-COOH exterior groups and cysteamine-capped GNP’s. CV was used for the detection of UA, with 34.5 nM LOD. Further, Malhotra et al. fabricated an amperometric biosensor after immobilization of uricase using the excellent properties of carbon nanotubes (CNTs) to detect UA concentration in serum samples. The developed enzymatic biosensor showed a rapid response of 8 s and LOD of 5 \(\mu\)M, having the stability of >180 days due to the employment of CNTs [76].

Recently, a non-enzymatic platform for electrochemical detection of UA was developed by Santos et al. in human urine [77]. In addition, Harraz and his co-worker’s reported a novel polypyrrole-carbon black-CO\(_3\)O\(_4\) (PPy-CB-CO\(_3\)O\(_4\)) nanocomposite for a non-enzymatic UA sensor using a modified glassy carbon electrode which showed linearity ranging from 0.75–305 \(\mu\)M having sensitivity (0.8786 \(\mu\)A \(\mu\)M\(^{-1}\) cm\(^{-2}\)), and lowest LOD of nearly ~ 0.46 \(\mu\)M in human blood serum [78].
Several works have been reported recently for electrochemical detection of urea [80,81]. Further, both urea and glucose can be measured utilizing a pH-switchable electrochemical sensor [82]. The detection is based on in situ pH-switchable enzyme-catalyzed processes in which urease catalyzed urea hydroxylation or glucose oxidase catalyzed glucose oxidation caused a change in the electrolyte’s pH, resulting in a distinct electrochemical response toward redox couple. Urea analysis was performed with DPV, CV, and EIS for the linear concentration (1 to 7 mM). In an enzyme-based method, an amperometric urea sensor was developed with an ITO electrode coated with multi-layered graphene [83]. Multi-layered graphene exhibited enhanced 2D surface area with improved electrical conductivity. Immobilization of urease and glutamate dehydrogenase enzymes was performed over the sensor’s surface that showed linearity for urea from 1.7 to 16.7 mM, with a 0.6 mM detection limit. In another study, a thin film of gelatin organogel-based nano-composite (GA-NC) was made onto an ITO (GA-NC/ITO) electrode by drop-casting and was utilized to detect urea. The developed GA-NC/ITO electrode exhibited a sensitivity of 5.56 and 32.7 μA mM⁻² cm⁻² in the two-concentration range of 2 to 20 and 0.1 to 2 mM, respectively [84]. A potentiometric urea sensor based on urease has also been
reported [85]. Immobilization of the enzyme was performed by physisorption over the electrodeposited polyaniline film or by attaching to the layered film of alternating chitosan and carboxymethyl pullulan made over a polyaniline film. The current response was linearly proportional to concentrations of urea ranging from 1 mM to 100 mM. Based on the enzyme implanted layered film, the sensor has better stability, which can be attributed to the polysaccharide coating’s protective quality. A gold electrode covered with chitosan-doped cadmium sulphide QDs was used as the primary substrate in an MIP-based urea voltammetric sensor [86]. Two linear ranges between 5 pM and 0.4 nM and 0.5 and 70 nM, for urea determination were shown using DPV, with 1 pM LOD.

Moreover, Bansi D Malhotra designed and developed various nanocomposites-based enzymatic bioelectrodes for urea detection. For instance, titania–zirconia (TiO$_2$–ZrO$_2$) nanocomposite integrated with a microfluidics system has been utilized for co-immobilization of urease (Urs) and glutamate dehydrogenase (GLDH) for the detection of urea [87]. The bioelectrode Urs-GLDH/TiO$_2$-ZrO$_2$/ITO showed a sensitivity of 2.74 µA [log mM]$^{-1}$ cm$^{-2}$ and a broad linearity of 5–100 mg dL$^{-1}$ with LOD of 0.44 mM. In another work, mesoporous silica particle anchored with graphene oxide (GO) hybrid system was used for urea detection having a sensitivity of 2.6 µA mM$^{-1}$ cm$^{-2}$ with LOD of 14 mg dL$^{-1}$ [88]. Additionally, glutamate dehydrogenase (GLDH) and urease (Urs) were covalently co-immobilized onto a self-assembled monolayer (SAM) comprising 10-carboxy-1-decanthiol (CDT) immobilized onto patterned gold (Au) electrodes for determination of urea utilizing poly(dimethyilsiloxane)-based (PDMS) microfluidic channels. The sensor showed a linearity ranging from 10–100 mg dL$^{-1}$, with LOD of 9 mg dL$^{-1}$ and high sensitivity of 7.5 µA mM$^{-1}$ cm$^{-2}$ [89]. Furthermore, an electrochemically immobilized film of biocompatible zirconia (ZrO$_2$) on gold-covered glass electrodes was used to make a urea biosensor by immobilizing Urs and GLDH. The urea biosensor achieved a linear response of up to 40 mg dL$^{-1}$ and sensitivity of 0.071 µA/(mM cm$^{-2}$) having stability of 4 months when kept in 4 °C [90].

2.1.5. Cholesterol

Cholesterol monitoring is critical, especially for patients with a higher threat of heart disease. Blood cholesterol levels must be measured to diagnose atherosclerosis and estimate the threat of thrombosis and cardiovascular disease. Total cholesterol levels in the blood should not exceed 5.17 mM; however, this value varies with age, weight, and gender. A measurement of 5.17–6.18 mM should be the threshold amount for total cholesterol concentration in a patient’s blood, which is regarded as very high [91]. Bansi D Malhotra made an enormous contribution towards the development of cholesterol biosensors. He developed several cholesterol biosensors via immobilization of cholesterol oxidase (ChOx) enzyme onto ITO electrodes modified with different types of nanomaterials and nanocomposites [92–100].

Mixing MIP-coated MWCNTs, silicon alkoxide and graphite powder, then collecting the resulting product as the electrode opening of a Teflon sleeve, a voltammetric cholesterol sensor-based MIP was constructed [101]. Linear sweep voltammetry (LSV) was utilized for cholesterol measurement depicting linearity from 10 to 300 nM, with a 1 nM detection limit. A glutaraldehyde-functionalized magnetic ferrite nanoparticles (GA-MNPs) and poly-(diallyldimethylammonium chloride)-coated MWCNTs (PDDA/MWCNTs) were used to fabricate an enzymatic amperometric cholesterol sensor [102]. Before adding GA-MNPs, the carboxylated MWCNTs were wrapped with the +ve charged PDDA. On the composite cast, the enzymes ChOx and HRP were co-immobilized and deposited over a GCE. The sensor showed a calibration curve range (0.01 to 0.95 mM) with a 0.85 µM detection limit. The same substrate was used for powering the cathodic and anodic electrocatalytic reactions, resulting in a reagent-free self-powered cholesterol detection platform [103][Figure 4ii]. Immobilization of cholesterol oxidase was performed in a sol–gel matrix, which was used to coat both the anode and cathode. At the anode, cholesterol oxidation catalysis is performed by cholesterol oxidase, whereas, at the cathode, Prussian blue
electrocatalytically decreased H₂O₂ due to the conversion of cholesterol enzymatic. The self-driven amperometric sensor was capable of measuring concentrations of cholesterol up to 4.1 mM.

A sensor based on amperometric triglyceride was made by mixing four enzymes that include glycerol-3-phosphate oxidase, HRP, lipase, and glycerol kinase, co-immobilized over the platinum electrode surface with poly(vinyl alcohol) membrane, a coating in another enzymatic technique [104]. In the range of 560 µM to 2.3 mM, the current response was proportional to the triglyceride concentration, with 210 µM LOD. A facile electrochemical micro paper-based analytical device (EuµPADs) and a commercial glucometer were integrated innovatively for cholesterol determination [105]. The sample and reference zones were defined by printed wax barriers on each EuµPAD, while the experimental strips were constructed of a single piece of paper or plastic. ChOx catalyzed the cholesterol to cholest-4-en-3-one conversion in the enzyme-mediated stage with simultaneous reduction of Fe(III) to [Fe(II) (CN)₆]⁴⁻ ions, and the Fe(II) formed was electrochemically evaluated. An amperometric cholesterol study showed a linear plot of 0.5 to 5.2 mM in human plasma with 340 µM LOD. A non-enzymatic voltammetric cholesterol sensor platform has also been published [106]. An electroactive and hydrophilic cholesterol detecting interface was created by altering a chemically transformed graphene with β-cyclodextrin and methylene blue. Methylene blue was eradicated from the matrix and transferred to buffer solution in the presence of cholesterol, where it was electrochemically detected. A linear curve ranging from 5–100 µM was developed using DPV, with 1 µM LOD as shown in Figure 4i.

2.1.6. Lactate

In the clinical investigation of acute cardiac disorders, respiratory insufficiency, and shock, the lactate level in the blood was used. Lactic acidosis is also known to occur in the presence of medication toxicity, left ventricular failure, and tissue hypoxia. Lactate physiological levels in the blood are between 0.5 and 2.2 mM [107].

Recently, flexible laser scribed graphitic carbon [108] and dual functional electrochemical sensor using macroscopic film of polyaniline-based (PANI) biosensors were reported for lactate detection [109]. The enzyme named Lactate oxidase was immobilized in the matrix of albumin/mucin hydrogel prepared over a platinum electrode surface to create an amperometric lactate biosensor [110]. By wrapping the electrode with a membrane of Nafion, the intrusion due to anionic species was reduced. In the region of 2 to 1000 µM, linearity of catalytic current based on lactate concentration was validated, with 0.8 µM LOD. The NAD⁺ and lactate dehydrogenase enzyme were co-immobilized over the GCE surface pre-coated with Fe₃O₄ magnetic nanoparticles and MWCNTs nanocomposite in another enzymatic technique. Lactate showed linearity ranging from 5 to 500 µM using a DPV technique, with 5 µM LOD [111]. For non-invasive lactate real-time monitoring, a printed amperometric sensor “tattoo” for the wearer’s skin was fabricated in sweat while exercising [112] [Figure 4iv]. The wearable sensor based on lactate oxidase displayed specificity for lactate showing a linear range to 20 mM and robustness towards epidermal wear. The gadget was tested on humans, and it was discovered that the lactate profiles accurately mirrored lactate generation in sweat at various exercise intensities. Using mixed Streptococcus thermophilus and Lactobacillus bulgaricus bacterial cultures and palygorskite, a bacterium stabilizing matrix attached over the O₂ electrode surface, whole cells were employed as a sensing probe for monitoring lactate [113]. The sensor’s amperometric response was linear, ranging from 0 to 300 µM. Two components were used to create an FET-based lactate sensor: (i) a pH-sensitive chemical field-effect transistor (FET) and (ii) a metallic microelectrode kept on sensitive gate [114], as shown in Figure 4iii. At the microscale, the presence of these two components is coupled with potentiometric and amperometric effects. Lactate may show linearity from 1 to 6 mM using this sensor.

The electrochemical entrapment of polyaniline (PANI) onto sol–gel-derived tetraethyloorthosilicate (TEOS) films deposited onto ITO-coated glass by Malhotra et al. has been utilized for immobilization of lactate dehydrogenase (LDH) [115]. The amperometric response
of the electrodes under optimum conditions exhibited a linear relationship from 1 mM to 4 mM. In another study for the immobilization of LDH for lactate detection, TEOS-derived sol–gel films were used. It was observed that TEOS-derived sol–gel films with physisorbed LDH had a linear response in the range of 0.5–4 mM, but those with LDH in a sandwich configuration had a linear response ranging from 0.5–3 mM l-lactate [116]. Further, the immobilization of LDH on electrochemically polymerized polypyrrole–polyvinylsulphonate (PPY–PVS) films was achieved to develop a lactate biosensor by Malhotra et al. [117]. The fabricated PPY–PVS–LDH electrodes showed LOD of $1 \times 10^{-4}$ M, a linear range of 0.5 to 6 mM for L-lactate detection, a response time of about 40 s, and stability of 2 weeks. Lactate oxidase (LoD) and lactate dehydrogenase (LDH) have been co-immobilized on electrochemically prepared PANI toward the detection of lactate by Malhotra et al. [118]. The PANI/LoD/LDH electrodes showed a linearity from 0.1–1 mM, having a detection limit of $5 \times 10^{-5}$ M, and stability of about 3 weeks.

Figure 4. (i) It demonstrates the cholesterol sensing mechanism, utilizing Grp-β-CD as the working substrate [Adapted with permission from ref. [106], Copyright 2015 Elsevier]; (ii) scheme showing a self–powered biosensor for measurements of cholesterol [Adapted with permission from ref. [103], Copyright 2014 ACS]; (iii) cross section (a) and details (b) of the ElecFET device for lactate detection (chip size: $3.5 \times 3.5$ mm$^2$) [Adapted with permission from ref. [114], Copyright 2013 Elsevier], and (iv) illustration of tattoo-based electrochemical biosensors for non-invasive lactate detection in human samples [Adapted with permission from ref. [112], Copyright 2013 ACS].

2.1.7. Hydrogen Peroxide (HP)

Reactive oxygen species, i.e., ROS, are considered intracellular signaling molecules that regulate cell apoptosis and DNA damage, among other things. On the other hand, the ROS accumulation in cells causes oxidative stress, which has been related to neurological illnesses, cancer, autoimmune diseases, and Alzheimer’s disease. Hydrogen peroxide (HP) is a commonly researched type of ROS in cells because it causes a batch of harmful biological changes. To completely understand the reactive species roles of cell physiology, specific
HP detection in cells and evaluation of its release mechanism are required [119]. Malhotra et al. [120–122] and others [123,124] fabricated a few enzymatic biosensing platforms for the detection of HP via immobilization of horseradish peroxidase enzyme.

An enzymatic voltammetric HP biosensor was created by HRP enzyme insertion into a matrix of cross-linked 3D polymer carrying a moveable osmium redox (Os$^{+/2}$) and allowing substrate diffusion. Collisions of the redox mediators delivered [125] electrons step-by-step to the enzyme from the electrode surface, reducing the analyte. According to CV, HP has a dynamic linearity ranging from 1–100 µM. Furthermore, HP detection via CA showed linearity from 1–10 nM, having a 1 nM LOD. Mesoporous carbon nanoparticles were employed to construct electrically linked enzyme electrodes to sense HP in a similar method [126]. Methylene blue was used to fill carbon NPs pores, which were subsequently HRP capped and fixed on the surface of GCE detecting up to 25 mM HP using CV.

A microperoxidase-11 enzyme mounted on a top MWCNTs-functionalized bacterial cellulose was used to create another enzymatic amperometric HP sensor [127]. A dynamic conductive film having great biocompatibility was created by modifying bacterial cellulose with MWCNTs. The proposed sensor could measure HP levels throughout a linear detection range (0.1–257.6 µM), having a detection limit of 0.1 µM. A catalase enzyme mounted on a top film of MWCNTs and L-lysine-modified GCE [128] was used to create an enzymatic amperometric sensor [Figure 5i]. The concentration from 1 µM–3.6 mM showed a linear current response to HP, with 8 nM LOD.

Because of the innate metal center activity inside the enzyme molecule, metalloproteins are commonly used as an HP sensing element. For example, a protein microarray was created using L-cysteine-modified Au-TiO$_2$ hydrophilic micropatterns, followed by immobilization of metalloprotein Cytochrome c [129]. Wide linearity for HP ranging from 1 nM to 10 mM was measured using amperometry, having a LOD of 2 nM, as shown in Figure 5ii. Using an imidazole-terminated self-assembled monolayer, HP amperometric sensor was recently constructed by directly connecting the heme center of Cytochrome c with the surface of gold ultra-microelectrode [130]. The HP level can be determined using this sensor with 3 µM LOD.

Another metalloprotein, hemoglobin, was used to fabricate an HP amperometric sensor via hemoglobin microbelts electrospinning over the surface of GCE [131]. Then, hemoglobin catalyzed the HP reduction over a linear range (10–230 µM) having a detection limit of 0.6 µM. Myoglobin was immobilized on an ITO covered with nanostructured porous cerium dioxide, a layer in another metalloprotein-based HP sensor [132]. With linearity of 3 mM and a LOD of 0.6 M, this sensor could detect HP. A heme peptide deposited onto a conductive 3D hybrid film of CNTs on graphene surface was also used to create an amperometric sensor for HP [133]. The film’s microvoids helped HP diffuse to the altered heme peptide, which resulted in a higher cathodic current. Over a range of 1–30 µM, the cathodic current increases in linear proportion with the HP concentrations. A derivative of zinc porphyrin-fullerene (C60) was encapsulated in a tetraoctyl ammonium bromide film and stored onto the surface of GCE [134] to provide another amperometric HP sensor. HP electrocatalytic reduction had wide linearity (35 µM–3.4 mM), having a LOD of 810 nM. Nanomaterials’ electrocatalytic activity has also been used to produce an HP sensing platform. By hydride reduction of manganese acetylacetonate in the presence of GNPs, core/shell Au/MnO nanoparticles were synthesized, which were then used to develop an amperometric HP sensor [135]. The HP was linearly determined ranging from 20 nM to 15.1 mM, having LOD of 8 nM.

An electrochemical HP sensor was created utilizing nitrogen-doped carbon nanotubes in a similar method (NCNTs) [136]. Compared to NCNTs and MWCNTs, it showed a robust electrocatalytic activity via a four-electron transfer procedure for reduction of O$_2$, while MWCNTs-mediated electrocatalysis uses a two-electron transfer process. This amperometric sensor offers a linear HP-level detection range (1.8 to 139 µM), having 370 nM detection limit. A 3D graphene network, i.e., 3DGN, was synthesized using chemical vapor deposition (CVD) in another HP nanomaterial-based experiment [137]. Pt
nanoparticles/3DGN, MWCNTs/3DGN, Pt/MWCNTs/3DGN, and MnO$_2$/3DGN were among the composites created using the 3DGN as a template. The Pt/MWCNTs/3DGN-based amperometric sensor showed a linear detection range for HP from 25 nM to 6.3 µM, with 8.6 nM LOD.

2.1.8. Ketone Bodies

Ketone bodies include acetoacetate, acetone, and 3-hydroxybutyrate. These biomarkers are related to diabetes, which points to critical ketoacidosis.

Lee and his collaborators have recently reported an enzymatic biosensor using gold (Au) electrode acetylaceic acid (AcAc) determination in a urine sample [138]. In addition, Yadav et al. has developed a perovskite BaSnO$_3$-based electrochemical biosensor for acetone sensing in the human breath [139]. Further, an enzyme-based voltammetric sensor for detection of 3-hydroxybutyrate was fabricated with immobilization of the enzyme (3-hydroxybutyrate dehydrogenase) over the SWCNTs-covered surface of SPE [140], as shown in Figure 5iii. CV was employed to analyze 3-hydroxybutyrate by detecting the signal from the production of 3-nicotinamide adenine dinucleotide (NADH) (enzymatic reaction product) by performing CV. A linear response was presented by calculating electrochemical readings with an increase in 3-hydroxybutyrate concentrations ranging between 0.1 to 2 mM, having a detection limit of 9 µM. A non-enzymatic voltammetric acetone sensor was prepared with GCE coated with ZnO nanoparticles [141]. There was a linear current increase with increasing acetone concentration (130 µM–1330 mM) and a 68 µM LOD.

2.1.9. Xanthine

Xanthine is considered an intermediary product of the purine nucleotide and deoxynucleotide metabolism. It is uric acid’s metabolic precursor, its initial sign of an unusual purine profile, and can hence be used as an indicator for various disorders, including hyperuricemia, gout, cerebral ischemia, and xanthinuria [142]. In urine, the physiological range of xanthine is 40 to 160 µM [143].

A xanthine enzymatic amperometric sensor was fabricated with modification of a 3D network of electro-polymerized GNPs capped with SWCNTs, p-aminophenol, 2-mercaptoethanesulfonic acid, and 1-adamantanethiol over GCE [144] [Figure 5iv]. β-cyclodextrin and xanthine oxidase were immobilized via host–guest interactions over the hybrid. This sensor had a linear detection of xanthine from 50 nM to 9.5 µM, having a 40 nM LOD. A non-enzymatic sensor for xanthine was fabricated with GCE altered with reduced graphene oxide (RGO) with a coating of poly(o-aminophenol-co-pyrogaloll) (PAP) electropolymerized film [145]. PAP synthesis was performed through the electrochemical copolymerization of pyrogallol and o-aminophenol in an acidic medium. The concentration of electropolymerized PAP was enhanced in the presence of RGO due to its huge availability of surface area. The amperometric analysis had a linear detection range for xanthine ranging from 1 to 120 µM, having a detection limit of 0.5 µM. Recently, development of an electrochemical biosensor using vanadium tetrasulfide nanospheres (VS$_4$) fixed into nitrogen-doped biomass-derived porous carbon materials (VS$_4$@N-BPC) was reported for electrochemical xanthine determination [146].
2.1.10. Hypoxanthine

Xanthine is a hypoxanthine product whose physiological level ranges from 10 μM to 30 μM in blood [147]. Hypoxanthine, via the production of oxygen radicals, plays an important part in post-hypoxic reoxygenation cell injury by and works as a hypoxia indicator [148].

An enzyme-based low-potential amperometric sensor for hypoxanthine and xanthine was fabricated with xanthine dehydrogenase enzyme immobilization on a PG electrode, which is an edge plane [149]. The enzyme oxidizes the hypoxanthine to xanthine, followed by xanthine conversion to uric acid through oxidative hydroxylation process. The electrode exhibited a proportional behavior to xanthine and hypoxanthine concentration, showing linearity from 10 μM to 1.8 mM, having a 0.25 nM detection limit.

2.1.11. Creatine

Creatine is a derivative of amino acid produced in the liver, kidneys, and pancreas from S-adenosylmethionine, L-arginine, and glycine. The stored creatine in muscular tissues is mainly transformed to phosphocreatine during the reversible reaction involving adenosine triphosphate (ATP), catalyzed via creatine kinase enzyme. Phosphocreatine is the body’s primary energy storage type. Creatinine levels in the blood and urine are utilized as a clinical diagnostic of muscle injury [150]. A combination of sarcosine oxidase and creatinase were co-immobilized on a carbon paste electrode (CPE) surface altered with Fe₃O₄ nanoparticles and used to make an enzymatic amperometric sensor for detection of creatine [151]. The sensor’s linearity ranges from 0.2–3.8 μM and 9 to 1200 μM, respectively, having a 0.2 μM detection limit.
2.1.12. Creatinine

Creatinine is a waste product of muscle metabolism used to assess renal function. A biochemical mechanism including creatine, phosphocreatine, and ATP produces creatinine. Creatinine levels should range from 53–115 µM in the blood.

By co-immobilizing the three enzymes, an enzymatic amperometric sensor was developed for creatinine: sarcosine oxidase, creatinine aminohydrolase, and creatine aminohydro-las on ZnO nanoparticles/chitosan/carboxylated MWCNTs/polyaniline coated composite film over the surface of a platinum electrode [152] [Figure 6ii]. The sensor displayed a linear response in the 10–650 µM, with a 0.5 µM LOD. A voltammetric creatinine sensor based on MIP has also been published [153]. In this study, the template molecule, i.e., creatinine was self-assembled over the Fe3O4 polyaniline NPs surface in the functional monomer aniline presence, as shown in Figure 6iii. The orderly structured MIP was formed through electro-polymerization on the surface of the electrode after magnetically directed preassembly GCE. With creatinine concentrations ranging from 20 nm to 1 µM, the DPV response was linearly detected, with 350 pM LOD.

Electro-polymerization was used to coat gold an electrode array having creatinine combined with pyrrole, resulting in a MIP-based amperometric sensor for detection of creatinine [154] [Figure 6i]. After that, the creatinine sample was combined with an anti-
creatinine antibody that had been HRP labeled, and the product was applied to the electrode surface to give a viable response with the creatinine fixed on the surface of the electrode. Amperometric tests were performed in the H$_2$O$_2$ and 3,3',5,5'-tетраметилбензидин (TMB) presence. The level of creatinine was estimated up to 1 mM using a circular, square wave. A non-enzymatic electrochemical method for detecting creatinine based on picrate anions consumption measurement due to reaction among the creatinine molecules, utilized an edge plane of pyrolitic graphite (PG) electrode [155]. The current examination showed two linear dynamic detection ranging from 0 to 6 and 6 to 11 mM for creatinine detection, with LOD of 720 µM.

Apart from these, recently Cui and his co-workers have developed a printed biosensor which is disposable for creatinine clinical determination during renal functioning [156]. In addition, a biosensor for detection of creatinine was also reported by a research group utilizing an Au electrode with graphene quantum dots suspended in Cu$^{2+}$ ions (Such Au/Nafion-GQDs-Cu) [157]. Further, Fatibello-Filho et al. have proposed a screen-printed microcell for creatinine electrochemical detection [158].

**Table 1.** Nanomaterial-based biosensing platform towards clinically relevant human metabolite detection.

| Metabolite | Nanomaterial Based Biosensing Platform | Electrochemical Technique | Limit of Detection (LOD) | Linear Detection Range (LDR) | Real Sample | Ref. |
|------------|--------------------------------------|---------------------------|--------------------------|-----------------------------|-------------|-----|
| Glucose    | Teflon-coated Pt/Ir wire Amperometry | 1.5 µM 5–800 µM | - | Tear [46] |
|            | µPEDs Chronoamperometric DPP | 1.0 ppb 0.2–22.6 mM | - | Urine [47] |
|            | PVA-CuO/ITO Capacitance | - 0.5–20 mM | - | [49] |
|            | uMED Chronoamperometry | - 50–500 mg dL$^{-1}$ | - | Blood [51] |
|            | Con A / Au Capacitance | 1.0 × 10$^{-6}$ M 1.0 × 10$^{-6}$ to 1.0 × 10$^{-2}$ M | - | - [54] |
|            | GOx/CeO$_2$–TiO$_2$/ITO DPV | 10 mg dL$^{-1}$ 0.56–22.2 mM | - | - [56] |
|            | GOx/NS-PANI/ITO DPV | 2.1 mM up to 400 mg dL$^{-1}$ | - | - [57] |
|            | GOx/CeO$_2$/Pt bio- DPV | 1.01 mM 25–300 mg dL$^{-1}$ | - | - [58] |
|            | ITO/PB/(PEI/PVS)$_n$(PEI/β-Gal)$_3$ | Amperometry 1.13 mmol L$^{-1}$ 1.13 mmol L$^{-1}$ | - | Milk [63] |
|            | Au-MPA-MWCNT-P(AMB-A)-PDA/CDH | Amperometry 0–30 mM | - | - [64] |
|            | P3HT/SA/b-gal/GaO | Amperometry 1–6 gdL$^{-1}$ | - | - [65] |
|            | P3HT/SA/ITO Amperometry | 1–4 gdL$^{-1}$ | - | Milk [66] |
|            | ITOP3HT/SA/GaO | Amperometry 0.05–0.5 g galactoseL$^{-1}$ | - | Blood [67] |
| Galactose  | NaF/UOx/Fc/GCE CV and DPV | 230 nM 500 nM to 600 µM | - | Blood [72] |
|            | BDD CV | 1 mM 250–1250 µM | - | Urine [73] |
|            | S-Au electrode | Amperometry 0.4 µM 2.5 µM to 5 mM | urine [74] |
|            | GCE/AuNP@cysteamine/PAMAM | CV 34.5 nM | - | Blood [75] |
|            | Uricase/MWCNT/PANI/ITO | CV 5 µM 0.005–0.6 mM | - | Serum [76] |
| Uric acid  | CS-rGO/Con A | EIS 1–7 mM | - | Serum [82] |
|            | Urs-GLDH/MLG/ITO CV | 0.6 mM 1.7–16.7 mM | - | - [83] |
|            | GA-NC/ITO CV | - 2–20 and 0.1–2 mM | - | - [84] |
|            | CdS QDs–MIPs/Au DPV | 1.0 × 10$^{-12}$ M 5.0 × 10$^{-12}$–7.0 × 10$^{-8}$ M | - | Serum [86] |
|            | Urs-GLDH/TiO$_2$–ZrO$_2$/ITO CV | 0.44 mM 5–100 mg dL$^{-1}$ | - | - [87] |
|            | Urs-GLDH/GOS/ITO CV | 2.1 mM 3.3–19.9 mM | - | - [88] |
|            | Urs-GLDH/CDT/Au CV | 9 mg dL$^{-1}$ 10–100 mg dL$^{-1}$ | - | - [89] |
|            | Urs-GLDH/ZrO$_2$/Au CV | 5 mg dL$^{-1}$ 5–100 mg dL$^{-1}$ | - | - [90] |
Table 1. Cont.

| Metabolite      | Nanomaterial Based Biosensing Platform                          | Electrochemical Technique | Limit of Detection (LOD) | Linear Detection Range (LDR) | Real Sample | Ref. |
|-----------------|-----------------------------------------------------------------|---------------------------|--------------------------|-----------------------------|-------------|------|
| Cholesterol     | ChEt-ChOx/PPY–MWCNT/PTS/ITO                                      | DPV                       | 0.04 mML⁻¹               | 4 × 10⁻⁴–6.5 × 10⁻³ ML⁻¹     | Serum       | [93] |
|                 | ChEt-ChOx/4-ATP/Au                                               | CV                        | 1.34 mM and 1.06 mM       | 25–400 mg dL⁻¹              | -           | [94] |
|                 | ChOx/nan-NiO-CHIT/ITO                                            | CV                        | 43.4 mg dL⁻¹              | 10–400 mg dL⁻¹              | -           | [95] |
|                 | ChOx/Glu/PANI-NT/ITO                                             | LSV                       | 1.18 mM                   | 25–500 mg dL⁻¹              | -           | [96] |
|                 | ChOx/PANI-CMC/ITO                                                |                           | 1.31 mM                   | 0.5–22 mM                   | -           | [97] |
| Lactate         | Pt electrode                                                    | Amperometry               | 0.8 μM                    | 2 to ~1000 μM               | Whole blood | [110]|
|                 | Fe₃O₄/MWCNT/LDH/NAD⁺/GC                                          | DPV                       | 5 μM                      | 50–500 μM                   | Serum       | [111]|
|                 | sol–gel/PANI/LDH                                                 | Amperometry               | -                         | 1–6 mM                      | -           | [114]|
|                 | PPy–PVS–LDH                                                     | Amperometry               | 1 × 10⁻⁴ M                 | 0.5–6 mM                    | -           | [117]|
| Hydrogen peroxide| HRP-PANI-ClO₄⁻⁻/ITO                                               | CV                        | 1.984 mM                   | 3–136 mM                    | -           | [120]|
|                 | HRP/PANI-CeO₂/ITO                                                | CV                        | 50 mM                     | 50–500 mM                   | -           | [121]|
|                 | HRP/NanoCeO₂/ITO                                                | CV                        | 0.5 μM                     | 1.0–170 μM                  | -           | [122]|
|                 | MP-11/MWCNTs–BC                                                 | CV                        | 0.1 μM                     | 0.1–257.6 μM                | -           | [127]|
|                 | Au–TiO₂/Cys                                                     | CV                        | 2 mM                      | 10⁻⁶–10⁻² M                 | -           | [129]|
| Ketone bodies   | Mb/CeO₂/ITO                                                     | CV                        | 0.6 μM                     | 0.2–5 mM                    | -           | [132]|
| Xanthine        | SWCNT-modified SPCE                                              | CV                        | 80 μM                      | 0.1–2 mM                    | Serum       | [140]|
|                 | ZnO NPs                                                         | I–V                       | 68 μM                      | 130 μM–1330 mM              | -           | [141]|
|                 | XO-CD/pAuNP/SWNT/GCE                                            | CV                        | 40 nM                      | 50 nM–9.5 μM                | -           | [144]|
|                 | PAP/RGO/GC                                                      | LSV                       | 0.5 μM                     | 1.0–120 μM                  | -           | [145]|
|                 | EPG/XDH                                                         | CV                        | 2.5 × 10⁻¹⁰ M              | 1.0 × 10⁻⁵–1.8 × 10⁻³ M     | -           | [149]|
| Creatinine      | ZnO-NPs/CHIT/c-MWCNT/PANI/Pr                                      | EIS                       | 0.5 μM                     | 10–650 μM                   | Blood       | [152]|
|                 | Fe₃O₄@PANI NPs                                                  | DPV                       | 0.35 nmol L⁻¹              | 2.0 × 10⁻⁸–1.0 × 10⁻⁸ mol L⁻¹| Urine and plasma | [153]|
|                 | Conducting polymer                                              | Amperometric              | 0.46 mg dL⁻¹               | 0–11.33 mg dL⁻¹             | Blood       | [154]|
|                 | EPPG                                                            | CV                        | 0.27 mM                    | 7.5–11.5 mM                 | Urine       | [155]|
|                 | Fe₃O₄-CPEE                                                      | EIS                       | 2.0 × 10⁻⁷ mol L⁻¹         | 2.0 × 10⁻⁷ to 3.8 × 10⁻⁶ mol L⁻¹| Commercial creatine powder | [151]|

2.2. Biosensors for Gut Metabolites Detection

The human gut microbiota is composed of many coexisting species of bacteria, eukaryotic viruses, archaea, bacteriophages, and fungi that work together to form a diverse ecosystem that can impact human physiology, behavior, and pathologies [159–161]. The microbiome is vital in human homeostasis, especially in relation to metabolism [162]. Several researchers have reported a relation between metabolite profile alteration with anomalous-gut microbiota of patients with various diseases such as metabolic liver disease, inflammatory bowel disease, and metabolic disorders such as malnutrition and obesity [163,164]. Scientific and medical communities have accumulated evidence on the strong bidirectional connection between intestinal microbiota’s metabolites with various diseases as shown in Figure 7. Table 2 summarized the nanomaterial-based platforms for gut metabolite detection.
There is substantial evidence that Trimethylamine-N-oxide (TMAO) is a crucial metabolite of gut bacteria. Gut microbiota degrades nutrients rich in trimethylamine (TMA)-containing substances such as choline, carnitine, and lecithin to produce TMAO [166]. Recently, researchers have linked TMAO to an elevated risk of developing complex illnesses such as CVDs, colorectal cancer, chronic kidney diseases, diabetes, obesity [167,168], acute coronary syndrome [169], atherosclerosis, pneumonia, etc. [170]. As a result, TMAO is developing as a critical prognostic and diagnostic biomarker that establishes its biological activities in human health and disease, and its analytical monitoring is critical in health management.

Lakshmi et al. [15] fabricated an electrochemical sensor based on molecularly imprinted polymer (MIP) for selective and sensitive TMAO detection in bodily fluids such as urine [Figure 8i]. The MIP design was centered on polypyrrole (PPy) that was made using a chemical oxidation polymerization technique in the presence and absence of TMAO. The detection response was measured using differential pulse voltammetry (DPV), which indicated a peak current reduction as TMAO concentrations were increased having sensitivity of 2.47 μA/mL ppm$^{-1}$ cm$^{-2}$ and a detection range of 1–15 ppm. In another article, using a polyallylamine hydrochloride-capped manganese dioxide (PAH@MnO$_2$) nanozyme and a plasma absorption pad/separation pad, a new “color-switch” approach was designed by Chang et al. for the quantitative determination of TMAO directly in whole blood without any pre-treatment step [Figure 8ii]. Through quantitative investigation, the limit of quantitation (LOQ) for TMAO of <6.7 μM was achieved with wide linearity ranging from 15.6–500 μM as proof of concept [171]. Waffo et al. [172] also fabricated an amperometric TMAO biosensor in which glucose oxidase (GOD), TMAO reductase (TorA), and catalase (Cat) were attached to the surface of the electrode, allowing enzymatic TMAO reduction measurements, as shown in Figure 8iii. The sensor depicted linearity for concentrations of TMAO that range between 2–15 mM, having sensitivity 2.75 ± 1.7 μA/mM, 33 s of response time, and 3 weeks stability.
Furthermore, Yi et al. [173] developed a unique TMAO detection technique based on microbial electrochemical technology that directly converts TMAO concentration into electrical signals [Figure 8iv]. This approach demonstrated broad linearity from 0–250 μM, low LOD (5.96 M), and high sensitivity (23.92 μA/μM). Furthermore, the determination procedure was completed in 600 s, having a 90% accuracy rate in actual serum.

2.2.2. Other Gut Metabolites

Among metabolites made by the microbiome, Indole and its derivatives, such as indole-3-propionic acid, indole-3-acetic, indoxyl-3-sulphate, and indole-3-aldehyde, are present in the gut [174]. Indole derivatives go to the blood through intestinal absorption, and then they go to the liver through the blood. In the liver, indole derivatives are transformed into indoxyl sulphate by sequential hydroxylation and sulfation by hepatic cytochrome oxidases CYP 2E1 and SULT1A1, respectively [175]. Indole-3-aldehyde (I3A) may show vast health consequences [176], including gut barrier function regulation, T cells [177], inflammation of the skin [178], inflammation of the central nervous system [179], and inflammation related to aging. Wang et al. [180] fabricated an E. coli strain having a single plasmid harboring a chimeric two-component device that determines I3A at 0.1 to 10 μM [Figure 9i]. This novel I3A biosensor enables the indole metabolites detection formed at distinct host–microbe connections and adds innovative components to synthetic biology uses.

Filik et al. [181] developed a graphene-screen-printed electrode-based (GR-SPE) sensor and its electro-activity in the presence of uramic toxin indoxyl sulphate (Inds S) was explored by cyclic and square-wave voltammetry. The output shows that the electrode exposed excellent electro-activity to uramic toxin Inds S, and the oxidation process of Inds

Figure 8. Development process of nanomaterial–based biosensors for TMAO detection: (i) scheme depicts the MIP synthesis and the development of an MIP/ITO electrode for detection of TMAO [Adapted with permission from ref. [15], copyright 2021 Springer Nature]; (ii) illustration of PAH@MnO2 synthesis and colorimetric TMAO determination principle based on proton deposition of HCl by TMAO [Adapted with permission from ref. [171], copyright 2021 MDPI]; (iii) TMAO biosensor with various components [Adapted with permission from ref. [172], copyright 2021 MDPI]; and (iv) schematic sketch of microbial electrochemical technology established for the TMAO detection [Adapted with permission from ref. [173], copyright 2022 Elsevier].
S is irreversible and pH dependent. The calibration curve shows the linearity with Inds S concentration varies from 0.5–80 µM with a lower limit of detection 0.064 µM. This GR-SPE shows satisfactory results in human serum and urine samples and can be a promising tool for the routine sensing applications. Michaela.et.al. [182] fabricated a carbon composite film electrode and a carbon paste electrode and measured their electrochemical behavior in the presence of Inds S. The developed sensors were capable of quantifying the limit of Inds S as 0.72 µmol L\(^{-1}\) for the carbon composite film electrode and 1.7 µmol L\(^{-1}\) for the carbon paste electrode.

TMA is a distinctive odor produced by the fish degradation after its death that results in degradation (TMAO) after enzymatic actions. TMA is practically non-existent in live marine fish, although TMAO is abundant. TMA concentration rises after death, and its detection has been described as an effective indicator of the freshness of fish [183,184]. Diallo et al. [184] developed a field effect transistor-based enzymatic biosensor focused on the TMA determination in the context of seafood freshness evaluation. The device was constructed using a membrane of an enzyme comprising flavin-containing monoxygenase three (FMO\(_3\)) cross-linked with bovine serum albumin (BSA) which was immobilized on silicon nitride. TMA biosensing sensitivity was established in the 0–8 ppm range, as shown in Figure 9ii.

Further, an amperometric and impedimetric biosensor based on the substitution of conducting polypyrrole with ferrocenyl has been fabricated for detecting TMA by Bourigua et al. [184] as shown in Figure 9iii. The biosensor fabrication was characterized by impedance, CV, and FT-IR measurements. Impedimetric and amperometric responses were examined as a function of the concentration of TMA ranging from 0.4 µg mL\(^{-1}\) to 80 µg mL\(^{-1}\). The impedance spectroscopy calibration curve demonstrates excellent sensitivity with a dynamic detection range that is stable for 16 days. Moreover, Mitsubayashi et al. constructed a biosensor by immobilizing FMO\(_3\) onto a dissolved oxygen electrode area for TMA detection [Figure 9iv]. The FMO\(_3\) attached biosensor with flow injection analysis (FIA) shows good linearity with high repeatability for TMA samples that range from 1.0 to 50.0 mmol L\(^{-1}\) [185].

Table 2. Nanomaterial-based biosensing platform towards clinically relevant gut metabolites detection.

| Metabolite          | Nanomaterial Based Biosensing Platform | Electrochemical Technique | Limit of Detection (LOD) | Linear Detection Range (LDR) | Real Sample                  | Ref.   |
|---------------------|---------------------------------------|---------------------------|--------------------------|-----------------------------|-------------------------------|--------|
| TMAO                | MIP/ITO                               | DPV                       | 1 ppm                    | 1–15 ppm                    | Urine                         | [15]   |
|                     | PAH@MnO\(_2\)                         | -                         | <6.7 µM                  | 15.6 to 500 µM              | Urine                         | [17]   |
|                     | TorA/GOD/Cat                          | Amperometry               | 10 µM                    | 2 µM–15 mM                  | Human serum                   | [172]  |
|                     | S.loihica PV-4                        | Chronoamperometry         | 5.96 lM                  | 0 to 250 µM                 | Real serum                    | [173]  |
| Indoxyl sulfate (IS)| GR-SPE                                | SWV                       | 0.064 µM                 | 0.5–80 µM                   | Human serum and urine          | [181]  |
| Carbon composite film electrode | Voltammetric                           | 0.72 µmol L\(^{-1}\)      | -                        | -                           | Urine                         | [182]  |
| Trimethylamine (TMA)| Organic field effect transistors (OFETs) | -                         | 0–8 ppm                  | -                           | Marine fishes and seafood     | [183]  |
|                     | Poly(Py-FMO\(_3\)-ferrocene-co-py)   | EIS                       | 0.4 g mL\(^{-1}\)        | 0.4–80 g mL\(^{-1}\)       | Fish extract                  | [184]  |
|                     | FMO\(_3\) immobilized biosensor      | -                         | -                        | 1.0–50.0 mmol L\(^{-1}\)   | Fish extract                  | [185]  |
Apart from the nanomaterial limitations, electrochemical biosensors deal with a stability issue due to the use of biomolecules as a reorganization element. Biomolecules have less shelf-life, thermal stability, and pH stability. Biomolecules such as antibody denature at room temperature which may influence the performance of the biosensor and the diagnosis as well.

Figure 9. (i) Schematic illustration of the design of an I3A biosensor and detection mechanism of I3A [Adapted with permission from ref. [180], copyright 2021 ACS]; (ii) schematic structure of En-OFETs device [Adapted with permission from ref. [183], copyright 2009 Elsevier]; (iii) illustration of the chemical process in the biosensor production based on functionalized polypyrrole [Adapted with permission from ref. [184], copyright 2011 Elsevier]; and (iv) the experimental setup for the flow injection analysis with the FMO attached biosensor is depicted schematically [Adapted with permission from ref. [185], copyright 2004 Elsevier].

3. Summary and Future Directions

In the past few decades, electrochemical sensors have gained many researchers’ attention due to their excellent analytical properties and as promising tools for clinical diagnostics. All the electrochemical analyses described in this review carry out quick, sensitive, specific, and affordable investigations of clinically significant human and gut molecules without including pre-concentration steps [Figure 10]. Yet, these methods go through several issues that must be discussed before implementing them for diagnostic purposes. Moreover, the developed biosensors can continuously monitor the target molecules in real time, so there are no requirements for regular sample collection, showing innovative paths for fast and simple testing. Moreover, the construction of biosensing platforms using nanoscale transducers requires new techniques which surpass mass-transfer limits by controlling the motion of the nanoscale fluid. The utilization of nanomaterials for the development of biosensors deal with the biocompatibility and toxicity issues that occur due to their very small size. The stability of the nanomaterials is also a point of consideration because with time the nanomaterials agglomerate, and increase in size, and may change their electro-activity which further changes the performance of the sensors when developed. Apart from the nanomaterial limitations, electrochemical biosensors deal with a stability issue due to the use of biomolecules as a reorganization element. Biomolecules have less
Although some improvement has been made in nanomaterial-based electrochemical sensing, more study/analysis is needed. In the future, genetic-profiling-based research would likely increase sensor demand, having enhanced multiplexing capabilities and dealing with multiple biomarkers in a minimum period of time. Moreover, synchronized determination of several analytes needs to have no or little cross-reaction among the target and receptor biomolecules. Therefore, the performance of electrochemical biosensors is based on the selection of receptors and the rational design of the nucleic acid probe. The modification of electrochemical sensors with advanced automated devices can lead to no human interference, i.e., widely available for point-of-care (POC) devices. The conventional techniques described here are primarily involved in the assay automation of crucial elements, such as sample preparation, yet still contain manual phases. On the other hand, the complete automation in electrochemical-based assays generates truthful results without the involvement of skilled persons.

These techniques are good enough in the lab, but to integrate them into clinical governance, artificial intelligence (AI) and Internet of medical things (IoMT) must be integrated with the biosensing concept [186]. Digital healthcare allows automated detection tools and integrated cloud products for traditional healthcare monitoring. This digital transformation improves access to quality healthcare for patients, clinicians, and remote communities. Ultrasound, thermometers, glucometers, and ECG readers are point-of-care (POC) devices with Internet access and cloud storage. These advances are vital for improving healthcare by modifying insulin levels and linking patients with clinicians. IoMT-enabled gadgets transform home healthcare. An intelligent home medicine dispensing system uploads the patient’s medical history to the cloud. It reminds doctors and patients to take medication and warns clinicians when people do not. Technological innovation, industrial adaptability, and urbanisation increase healthcare system demands [187,188].

In summary, the most important challenges should be discussed before clinical use approval of electrochemical sensors. Nevertheless, the extraordinary hard work performed by the researchers' society allows for tremendous optimism that this approach will be proficient in the future. In addition, the present review is focused on the electrochemical-based
biosensors for the detection of various metabolites, but several other sensors/biosensors have been developed based on optical, fluorescence, and colorimetric approaches for metabolite detection. So, there is an opportunity for researchers to summarize the optical, fluorescence, and colorimetric-based work in future.

4. Conclusions

Processed foods, which are prevalent in Western diets, may contribute significantly to the increase of acquired metabolic disorders in developed nations. The requirement for high-performance detection equipment has risen in response to the sudden progress in detecting biomarkers that are indicators of disease. In conclusion, clinically relevant human and gut metabolites are extremely important in assessing biofluids. Electrochemical techniques in clinics could provide a viable solution to the rising demand for quick, selective, low-cost, and completely automated biomarker analysis. The advancement and progress of electrochemical sensors for clinically relevant gastrointestinal metabolites and biomolecules are discussed in this review article. Yet, there are still issues with analyte selectivity and determining the accurate concentration of unbound vs. bound analytes. Evaluating the response of biosensors for bound and unbound analytes in buffer and the influence of pH on the biosensor response could help in the systematic discovery of optimal sensing parameters and alleviate the challenges of monitoring very low concentrations in aqueous fluids. Furthermore, we recommend that complex fluid-sensing abilities be rigorously tested and reported in accordance with the concentrations encountered in samples such as diluted or undiluted biofluids.

Author Contributions: Writing—original draft preparation, A.K.Y., D.V., R.K.S., M.P., S.K.Y. and A.K.V.; writing—review and editing, A.K.Y., D.V. and P.R.S.; supervision, P.R.S. All authors have contributed to the article, read and approved the submitted version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: PRS highly acknowledges the Indian Council of Medical Research (ICMR) (sponsored project No. 34/13/2019-TF/Nano/BMS), New Delhi, India, and Biomedical Devices and Technology Development (BDTD) (funded project No. TDP/BDTD/49/2021) General, Department of Science and Technology (DST), New Delhi, India for financial aid. AKY is highly grateful to the Ministry of Education, Govt. of India for the Prime Minister Research Fellowship (PMRF) for helping him financially.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no commercial or financial conflict of interest during the research.

Abbreviations

P3HT, poly(3-hexyl thiophene); SA, stearic acid; ITO, indium tin oxide; S-Au electrode, sulfur-adlayer-coated gold; AuNp@cysteamine, cysteamine-capped gold nanoparticles; PAMAM, poly(amidoamine); GCE, Glassy carbon electrodes; BDD, boron doped diamond; Naf, Nanion; UOx, uricase; Fc, ferrocene; MWCNT, multi-walled carbon nanotube; PANI, polyaniline; CS, chitosan; rGO, reduced graphene oxide; ConA, concanavalin A; MLG, Multilayered graphene; GLDH, glutamate dehydrogenase; GA-NC, gelatin organogel-based nanocomposite; Au, gold; MIPs, Molecularly imprinted polymers; TiO$_2$–ZrO$_2$, titania–zirconia; Urs, Urease; ChOx, Cholesterol oxidase; CHIT, chitosan; NiO, nanostructured nickel oxide; PANI-CMC, polyaniline-carboxymethyl cellulose; ElecFET, Electrochemical Field Effect Transistor; LDH, lactate dehydrogenase; PPy-PVS, polypyrrole-polyvinylsulphonate; ClO$_4^-$, perchlorate; MP-11, microperoxidase-11; PAP, Poly(o-aminophenol-co-pyrogallol); RGO/GC, reduced graphene oxide/glassy carbon; ZnO-NPs/CHIT/c-MWCNT/PANI, zinc oxide nanoparticles/chitosan/carboxylated multiwall carbonnanotube/polyaniline; EPPG, Edge Plane...
Pyrolytic Graphite; SERS, Surface enhanced Raman spectroscopy; HPLC, High performance liquid chromatography; SPE, Solid phase extraction; UA, Uric acid; CA, Chronoamperometry; EIS, Electrochemical impedance spectroscopy; DPF, Differential pulse voltammetry; SWV, Square wave voltammetry; LSV, Linear sweep voltammetry; CV, Cyclic voltammetry; GO, Graphene oxide; CNT, Carbon nanotube; SWCNT, Single-walled carbon nanotube; LOD, Limit of detection; PPY, Poly(pyrrrole); CD, Cycloexetrin; MCPE, Modified carbon paste electrode; SPCE, Screen printed carbon electrode.

References

1. Kelly, T.; Yang, W.; Chen, C.-S.; Reynolds, K.; He, J. Global Burden of Obesity in 2005 and Projections to 2030. *Int. J. Obes.* 2008, 32, 1431–1437. [CrossRef]
2. Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global Estimates of the Prevalence of Diabetes for 2010 and 2030. *Diabetes Res. Clin. Pract.* 2010, 87, 4–14. [CrossRef]
3. Chen, Y.; Michalak, M.; Agellon, L.B. Focus: Nutrition and Food Science: Importance of Nutrients and Nutrient Metabolism on Human Health. *Yale J. Biol. Med.* 2018, 91, 95.
4. Misra, A.; Khurana, L. Obesity and the Metabolic Syndrome in Developing Countries. *J. Clin. Endocrinol. Metab.* 2008, 93, s9–s30. [CrossRef]
5. GBD 2016 Risk Factor Collaborators. Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016. *Lancet* 2017, 390, 1345. [CrossRef]
6. Jalandra, R.; Dalal, N.; Yadav, A.K.; Verma, D.; Sharma, M.; Singh, R.; Khosla, A.; Kumar, A.; Solanki, P.R. Emerging Role of Trimethylamine-N-Oxide (TMAO) in Colorectal Cancer. *Appl. Microbiol. Biotechnol.* 2021, 105, 7651–7660. [CrossRef] [PubMed]
7. Dalal, N.; Jalandra, R.; Bayal, N.; Yadav, A.K.; Sharma, M.; Makhrinia, G.K.; Kumar, P.; Singh, R.; Solanki, P.R.; Kumar, A. Gut Microbiota-Derived Metabolites in CRC Progression and Causation. *J. Cancer Res. Clin. Oncol.* 2021, 147, 3141–3155. [CrossRef] [PubMed]
8. Wang, Z.; Zhao, Y. Gut Microbiota Derived Metabolites in Cardiovascular Health and Disease. *Protein Cell* 2018, 9, 416–431. [CrossRef]
9. Brial, F.; Le Lay, A.; Dumas, M.E.; Gauguier, D. Implication of Gut Microbiota Metabolites in Cardiovascular and Metabolic Diseases. *Cell. Mol. Life Sci.* 2018, 75, 3977–3990. [CrossRef]
10. Zeng, H.; Umar, S.; Rust, B.; Lazarova, D.; Bordonaro, M. Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer. *Int. J. Mol. Sci.* 2019, 20, 1214. [CrossRef]
11. Caspani, G.; Kennedy, S.; Foster, J.A.; Swann, J. Gut Microbial Metabolites in Depression: Understanding the Biochemical Mechanisms. *Microb. Cell* 2019, 6, 454. [CrossRef] [PubMed]
12. Louis, P.; Hold, G.L.; Flint, H.J. The Gut Microbiota, Bacterial Metabolites and Colorectal Cancer. *Nat. Rev. Microbiol.* 2014, 12, 661–672. [CrossRef] [PubMed]
13. Vickers, N.J. Animal Communication: When I’m Calling You, Will You Answer Too? *Curr. Biol.* 2017, 27, R713–R715. [CrossRef]
14. Yang, G.; Chen, S.; Deng, B.; Tan, C.; Deng, J.; Zhu, G.; Yin, Y.; Ren, W. Implication of G Protein-Coupled Receptor 43 in Intestinal Inflammation: A Mini-Review. *Front. Immunol.* 2018, 9, 1434. [CrossRef]
15. Lakshmi, G.; Yadav, A.K.; Mehlawat, N.; Jalandra, R.; Solanki, P.R.; Kumar, A. Gut Microbiota Derived Trimethylamine N-Oxide (TMAO) Detection through Molecurally Imprinted Polymer Based Sensor. *Sci. Rep.* 2021, 11, 1338. [CrossRef]
16. Panahi, Z.; Custer, L.; Halpern, J.M. Recent Advances in Non-Enzymatic Electrochemical Detection of Hydrophobic Metabolites in Biofluids. *Sens. Actuators Rep.* 2021, 3, 100051. [CrossRef]
17. Keshavarz, M.; Tan, B.; Venkatakrishnan, K. Label-Free SERS Quantum Semiconductor Probe for Molecular-Level and in Vitro Cellular Detection: A Noble-Metal-Free Methodology. *ACS Appl. Mater. Interfaces* 2018, 10, 34886–34904. [CrossRef]
18. Morla-Folch, J.; Gisbert-Quilis, P.; Masetti, M.; Garcia-Rico, E.; Alvarez-Puebla, R.A.; Guerrini, L. Conformational SERS Classification of K-Ras Point Mutations for Cancer Diagnostics. *Angew. Chemie* 2017, 129, 2421–2425. [CrossRef]
19. Li, W.; Wu, F.; Dai, Y.; Zhang, J.; Ni, B.; Wang, J. Poly (Octadecyl Methacrylate-Co-Trimethylolpropane Trimethacrylate) Monolithic Column for Hydrophobic in-tube Solid-Phase Microextraction of Chlorophenoxy Acid Herbicides. *Molecules* 2019, 24, 1678. [CrossRef]
20. Jalandra, R.; Yadav, A.K.; Verma, D.; Dalal, N.; Sharma, M.; Singh, R.; Kumar, A.; Solanki, P.R. Strategies and Perspectives to Develop SARS-CoV-2 Detection Methods and Diagnostics. *Biomed. Pharmacother.* 2020, 129, 110446. [CrossRef]
21. Yadav, A.K.; Verma, D.; Kumar, A.; Kumar, P.; Solanki, P.R. The Perspectives of Biomarker-Based Electrochemical Immunosensors, Artificial Intelligence and the Internet of Medical Things Towards COVID-19 Diagnosis and Management. *Mater. Today Chem.* 2021, 20, 100443. [CrossRef] [PubMed]
22. Yadav, A.K.; Dhiman, T.K.; Lakshmi, G.; Berlina, A.N.; Solanki, P.R. A Highly Sensitive Label-Free Amperometric Biosensor for Norfloxacin Detection Based on Chitosan-Ytrria NanoComposite. *Int. J. Biol. Macromol.* 2020, 151, 566–575. [CrossRef] [PubMed]
23. Verma, D.; Yadav, A.K.; Mukherjee, M.D.; Solanki, P.R. Fabrication of a Sensitive Electrochemical Sensor Platform Using Reduced Graphene Oxide-Molybdenum Trioxide Nanocomposite for BPA Detection: An Endocrine Disruptor. J. Environ. Chem. Eng. 2021, 9, 105504. [CrossRef]

24. Verma, D.; Chauhan, D.; Mukherjee, M.D.; Ranjan, K.R.; Yadav, A.K.; Solanki, P.R. Development of MWCNT Decorated with Green Synthesized AgNps-Based Electrochemical Sensor for Highly Sensitive Detection of BPA. J. Appl. Electrochem. 2021, 51, 447–462. [CrossRef]

25. Yadav, A.K.; Verma, D.; Solanki, P.R. Electrophoretically Deposited L-Cysteine Functionalized MoS2@MWCNT Nanocomposite Platform: A Smart Approach toward Highly Sensitive and Label-Free Detection of Gentamicin. Mater. Today Chem. 2021, 22, 100567. [CrossRef]

26. Yadav, A.K.; Verma, D.; Lakshmi, G.; Eremin, S.; Solanki, P.R. Fabrication of Label-Free and Ultrasensitive Electrochemical Immunosensor Based on Molybdenum Disulfide Nanoparticles Modified Disposable ITO: An Analytical Platform for Antibiotic Detection in Food Samples. Food Chem. 2021, 363, 130245. [CrossRef]

27. Chaudhary, N.; Yadav, A.K.; Sharma, J.G.; Solanki, P.R. Designing and Characterization of a Highly Sensitive and Selective Biosensing Platform for Ciprofloxacin Detection Utilizing Lanthanum Oxide Nanoparticles. J. Environ. Chem. Eng. 2021, 9, 106771. [CrossRef]

28. Chauhan, D.; Yadav, A.K.; Solanki, P.R. Carbon Cloth-Based Immunosensor for Detection of 25-Hydroxy Vitamin D3. Microchim. Acta 2021, 188, 145. [CrossRef]

29. Yadav, A.K.; Verma, D.; Chaudhary, N.; Kumar, A.; Solanki, P.R. Aptamer Based Switches: A Futuristic Approach for Helicobacter Pylori Detection. Mater. Lett. 2022, 308, 131239. [CrossRef]

30. Yadav, A.K.; Verma, D.; Sharma, R.; Thakkar, A.; Solanki, P.R. Silane Modified Disposable ITO Electrode-Based Biosensor for Sperm Protein 17 Detection as a Novel Cancer Biomarker. SPAST Abstr. 2021, 1.

31. Sen, R.K.; Prabhakar, P.; Bisht, N.; Patel, M.; Mishra, S.; Yadav, A.K.; Venu, D.V.; Gupta, G.K.; Solanki, P.R.; Ramakrishnan, S. 2D Materials-Based Aptamer Biosensors: Present Status and Way Forward. Curr. Med. Chem. 2021, 28. [CrossRef] [PubMed]

32. Zhao, Y.; Barrere-Cain, R.E.; Yang, X. Nutritional Systems Biology of Type 2 Diabetes. Genes Nutr. 2015, 10, 31. [CrossRef] [PubMed]

33. Hood, L.; Heath, J.R.; Phelps, M.E.; Lin, B. Systems Biology and New Technologies Enable Predictive and Preventative Medicine. Science 2004, 306, 640–643. [CrossRef] [PubMed]

34. Sauer, R.T.; Pabo, C.O. Protein-DNA Recognition. Annu. Rev. Biochem. 1984, 53, 293–321.

35. D’Orazio, P. Biosensors in Clinical Chemistry. Clin. Chim. acta 2003, 334, 41–69. [CrossRef]

36. Parisi, O.I.; Dattilo, M.; Patitucci, F.; Malivindi, R.; Pezzi, V.; Perrotta, I.; Ruffo, M.; Amone, F.; Puoci, F. “Monoclonal-Type” Plastic Antibodies for SARS-CoV-2 Based on Molecularly Imprinted Polymers. BioRxiv 2020.

37. Kelley, S.O. Disease Detector. Sci. Am. 2015, 313, 48–51. [CrossRef]

38. Verma, D.; Dhiman, T.K.; Das Mukherjee, M.; Solanki, P.R. Electrophoretically Deposited Green Synthesized Silver Nanoparticles Anchored in Reduced Graphene Oxide Composite Based Electrochemical Sensor for Detection of Bisphenol A. J. Electrochem. Soc. 2021, 168, 097504. [CrossRef]

39. Verma, D.; Ranjan, K.R.; Mukherjee, M.D.; Solanki, P.R. Bioinspired Synthesis of Hematite Nanoparticles-Reduced Graphene Oxide Composite for Application in Bisphenol a Detection: A New in-Sight. Biosens. Bioelectron. X 2022, 11, 100217. [CrossRef]

40. Verma, D.; Kumar, A.; Rathee, G.; Dhiingra, K.; Mukherjee, M.D.; Solanki, P.R. Prospects of Nanomaterial-Based Biosensors: A Smart Approach for BPA Detection in Dental Sealants. J. Electrochem. Soc. 2022, 169, 027516. [CrossRef]

41. Verma, D.; Singh, K.R.B.; Yadav, A.K.; Nayar, V.; Singh, J.; Solanki, P.R.; Singh, R.P. Internet of Things (IoT) in Nano-Integrated Wearable Biosensor Devices for Healthcare Applications. Biosens. Bioelectron. X 2022, 11, 100153. [CrossRef]

42. Wang, J. Electrochemical Glucose Biosensors. Chem. Rev. 2008, 108, 814–825. [CrossRef] [PubMed]

43. Heller, A.; Feldman, B. Electrochemical Glucose Sensors and Their Applications in Diabetes Management. Chem. Rev. 2008, 108, 2482–2505. [CrossRef] [PubMed]

44. Vaddiraju, S.; Tomazos, I.; Burgess, D.J.; Jain, F.C.; Papadimitrakopoulos, F. Emerging Synergy between Nanotechnology and Implantable Biosensors: A Review. Biosens. Bioelectron. 2010, 25, 1553–1565. [CrossRef]

45. Labib, M.; Hedström, M.; Amin, M.; Mattiasson, B. Competitive Capacitive Biosensing Technique (CCBT): A Novel Technique for Monitoring Low Molecular Mass Analytes Using Glucose Assay as a Model Study. Anal. Bioanal. Chem. 2010, 397, 1217–1224. [CrossRef]

46. Yan, Q.; Peng, B.; Su, G.; Cohan, B.E.; Major, T.C.; Meyerhoff, M.E. Measurement of Tear Glucose Levels with Amperometric Glucose Biosensor/Capillary Tube Configuration. Anal. Chem. 2011, 83, 8341–8346. [CrossRef]

47. Nie, Z.; Nijhuis, C.A.; Gong, J.; Chen, X.; Kumachev, A.; Martinez, A.W.; Narovlyansky, M.; Whitesides, G.M. Electrochemical Sensing in Paper-Based Microfluidic Devices. Lab Chip 2010, 10, 477–483. [CrossRef]

48. Lankelma, J.; Nie, Z.; Carrilho, E.; Whitesides, G.M. Based Analytical Device for Electrochemical Flow-Injection Analysis of Glucose in Urine. Anal. Chem. 2012, 84, 4147–4152. [CrossRef]

49. Dhiman, T.K.; Lakshmi, G.; Kumar, R.; Asokan, K.; Solanki, P.R. Non-Enzymatic Detection of Glucose Using a Capacitive Nanobiosensor Based on PVA Capped CuO Synthesized via Co-Precipitation Route. IEEE Sens. J. 2020, 20, 10415–10423. [CrossRef]
101. Tong, Y.; Li, H.; Guan, H.; Zhao, J.; Majeeed, S.; Anjum, S.; Liang, F.; Xu, G. Electrochemical Cholesterol Sensor Based on Carbon Nanotube-Molecularly Imprinted Polymer Modified Ceramic Carbon Electrode. *Biosens. Bioelectron.* 2013, 47, 553–558. [CrossRef] [PubMed]

102. Egúilaz, M.; Villalonga, R.; Yáñez-Sedeño, P.; Pingarrón, J.M. Designing Electrochemical Interfaces with Functionalized Magnetic Nanoparticles and Wrapped Carbon Nanotubes as Platforms for the Construction of High-Performance Biorezyme Biosensors. *Anal. Chem.* 2011, 83, 7807–7814. [CrossRef] [PubMed]

103. Sekretaryova, A.N.; Beni, V.; Eriksson, M.; Karyakin, A.A.; Turner, A.P.F.; Vagin, M.Y. Cholesterol Self-Powered Biosensor. *Anal. Chem.* 2014, 86, 9540–9547. [CrossRef] [PubMed]

104. Pundir, C.S.; Singh, B.S.; Narang, J. Construction of an Amperometric Triglyceride Biosensor Using PVA Membrane Bound Enzymes. *Clin. Biochem.* 2010, 43, 467–472. [CrossRef]

105. Nie, Z.; Deiss, F.; Liu, X.; Akbulut, O.; Whitesides, G.M. Integration of Paper-Based Microfluidic Devices with Commercial Electrochemical Readers. *Lab Chip* 2010, 10, 3163–3169. [CrossRef]

106. Agnihotri, N.; Chowdhury, A.D.; De, A. Non-Enzymatic Electrochemical Detection of Cholesterol Using β-Cyclodextrin Functionalized Graphene. *Biosens. Bioelectron.* 2013, 43, 212–217. [CrossRef]

107. Bakker, J.; Gris, P.; Coffernils, M.; Kahn, R.J.; Vincent, J.-L. Serial Blood Lactate Levels Can Predict the Development of Multiple Organ Failure Following Septic Shock. *Am. J. Surg.* 1996, 171, 221–226. [CrossRef]

108. Madden, J.; Vaughan, E.; Thompson, M.; O’Riordan, A.; Galvin, P.; Iacopino, D.; Teixeira, S.R. Electrochemical Sensor for Enzymatic Lactate Detection Based on Laser-Scribed Graphitic Carbon Modified with Platinum, Chitosan and Lactate Oxidase. *Talanta* 2022, 246, 125349. [CrossRef]

109. Zhu, C.; Xue, H.; Zhao, H.; Fei, T.; Liu, S.; Chen, Q.; Gao, B.; Zhang, T. A Dual-Functional Polyaniline Film-Based Flexible Electrochemical Sensor for the Detection of PH and Lactate in Sweat of the Human Body. *Talanta* 2022, 242, 123289. [CrossRef]

110. Romero, M.R.; Ahumada, P.; Garay, F.; Baruzzi, A.M. Amperometric Biosensor for Direct Blood Lactate Detection. *Anal. Chem.* 2010, 82, 5568–5572. [CrossRef]

111. Teymourian, H.; Salimi, A.; Hallaj, R. Low Potential Detection of NADH Based on Fe3O4 Nanoparticles/Multiwalled Carbon Nanotubes Composite: Fabrication of Integrated Dehydrogenase-Based Lactate Biosensor. *Biosens. Bioelectron.* 2012, 33, 60–68. [CrossRef] [PubMed]

112. Jia, W.; Bandodkar, A.J.; Valdès-Ramírez, G.; Windmiller, J.R.; Yang, Z.; Ramírez, J.; Chan, G.; Wang, J. Electrochemical Tattoo Biosensors for Real-Time Noninvasive Lactate Monitoring in Human Perspiration. *Anal. Chem.* 2013, 85, 6553–6560. [CrossRef] [PubMed]

113. Chen, J.; Jin, Y. Sensitive Lactate Determination Based on Acclimated Mixed Bacteria and Polygorskite Co-Modified Oxygen Electrode. *Bioelectrochemistry* 2011, 80, 151–154. [CrossRef] [PubMed]

114. Diallo, A.K.; Djeghlaf, L.; Mazenq, L.; Launay, J.; Sant, W.; Temple-Boyer, P. Development of PH-Based ElecFET Biosensors for Lactate Ion Detection. *Biosens. Bioelectron.* 2015, 40, 291–296. [CrossRef] [PubMed]

115. Chaubey, A.; Pande, K.K.; Malhotra, B.D. Application of Polyaniline/Sol-Gel Derived Tetraethylorthosilicate Films to an Amperometric Lactate Biosensor. *Anal. Chem.* 2003, 19, 1477–1480. [CrossRef]

116. Chaubey, A.; Gerard, M.; Singh, V.S.; Malhotra, B.D. Immobilization of Lactate Dehydrogenase on Tetraethylorthosilicate-Derived Sol-Gel Films for Application to Lactate Biosensor. *Appl. Biochem. Biotechnol.* 2001, 96, 303–311. [CrossRef]

117. Chaubey, A.; Gerard, M.; Singhal, R.; Singh, V.S.; Malhotra, B.D. Immobilization of Lactate Dehydrogenase on Electrochemically Prepared Polyvinylpyrrolidone-Polyvinylsulphonate Composite Films for Application to Lactate Biosensors. *Electrochim. Acta* 2001, 46, 723–729. [CrossRef]

118. Chaubey, A.; Pande, K.K.; Singh, V.S.; Malhotra, B.D. Co-Immobilization of Lactate Oxidase and Lactate Dehydrogenase on Conducting Polyaniline Films. *Anal. Chim. Acta* 2000, 407, 97–103. [CrossRef]

119. Trachootham, D.; Alexandre, J.; Huang, P. Targeting Cancer Cells by ROS-Mediated Mechanisms: A Radical Therapeutic Approach? *Nat. Rev. Drug Discov.* 2009, 8, 579–591. [CrossRef]

120. Solanki, P.R.; Kaushik, A.; Ansari, A.A.; Sumana, G.; Malhotra, B.D. Horseradish Peroxidase Immobilized Polyaniline for Hydrogen Peroxide Sensor. *Polym. Adv. Technol.* 2011, 22, 903–908. [CrossRef]

121. Ansari, A.A.; Sumana, G.; Khan, R.; Malhotra, B.D. Polyaniline-Cerium Oxide Nanocomposite for Hydrogen Peroxide Sensor. *J. Nanosci. Nanotechnol.* 2009, 9, 4679–4685. [CrossRef]

122. Ansari, A.A.; Solanki, P.R.; Malhotra, B.D. Hydrogen Peroxide Sensor Based on Horseradish Peroxidase Immobilized Nanostuctured Cerium Oxide Film. *J. Biotechnol.* 2009, 142, 179–184. [CrossRef] [PubMed]

123. Verma, S.; Mal, D.S.; de Oliveira, P.R.; Janegitz, B.C.; Prakash, J.; Gupta, R.K. A Facile Synthesis of Novel Polyaniline/Graphene Nanocomposite Thin Films for Enzyme-Free Electrochemical Sensing of Hydrogen Peroxide. *Mol. Syst. Des. Eng.* 2022, 7, 158–170. [CrossRef]

124. Portorro-Bottier, A.; Gutiérrez-Tarriño, S.; Calvente, J.J.; Andreu, R.; Roldán, E.; Oña-Burgos, P.; Olloqui-Sariego, J.L. Enzyme-like Activity of Cobalt-MOF Nanosheets for Hydrogen Peroxide Electrochemical Sensing. *Sensors Actuators B Chem.* 2022, 368, 132129. [CrossRef]

125. Suraniti, E.; Ben-Amor, S.; Landry, P.; Rigoulet, M.; Fontaine, E.; Bottari, S.; Devin, A.; Sójic, N.; Mano, N.; Arbault, S. Electrochemical Monitoring of the Early Events of Hydrogen Peroxide Production by Mitochondria. *Angew. Chemie* 2014, 126, 6773–6776. [CrossRef]
126. Trifonov, A.; Herkendell, K.; Tel-Vered, R.; Yehezkeli, O.; Woerner, M.; Willner, I. Enzyme-Capped Relay-Functionalized Mesoporous Carbon Nanoparticles: Effective Bioelectrocatalytic Matrices for Sensing and Biofuel Cell Applications. *ACS Nano* **2013**, *7*, 11358–11368. [CrossRef] [PubMed]

127. Zhang, B.; Zhou, J.; Li, S.; Zhang, X.; Huang, D.; He, Y.; Wang, M.; Yang, G.; Shen, Y. Hydrogen Peroxide Biosensor Based on Microperoxidase-11 Immobilized on Flexible MWCNTs-BC Nanocomposite Film. *Talanta* **2015**, *131*, 243–248. [CrossRef]

128. Villan, A.T.E.; Chen, S.M.; Lou, B.S. A Simple Strategy for the Immobilization of Catalase on Multi-Walled Carbon Nanotube/Poly (L-Lysine) Biocomposite for the Detection of H<sub>2</sub>O<sub>2</sub> and Iodate. * Biosens. Bioelectron.* **2014**, *61*, 639–647. [CrossRef]

129. Li, X.; Liu, Y.; Zhu, A.; Luo, Y.; Deng, Z.; Tian, Y. Real-Time Electrochemical Monitoring of Cellular H<sub>2</sub>O<sub>2</sub> Integrated with in Situ Selective Cultivation of Living Cells Based on Dual Functional Protein Microarrays at Au—TiO<sub>2</sub> Surfaces. *Anal. Chem.* **2010**, *82*, 6512–6518. [CrossRef]

130. Salamifar, S.E.; Lee, S.; Lai, R.Y. Electrochemical Hydrogen Peroxide Sensors Fabricated Using Cytochrome c Immobilized on Macroelectrodes and Ultramicroelectrodes. *Colloids Surf. B Biointerfaces* **2014**, *123*, 866–869. [CrossRef]

131. Ding, Y.; Wang, Y.; Li, B.; Lei, Y. Electrospun Hemoglobin Microbelts Based Biosensor for Sensitive Detection of Hydrogen Peroxide and Nitrite. *Biosens. Bioelectron.* **2010**, *25*, 2009–2015. [CrossRef]

132. Yagati, A.K.; Lee, T.; Min, J.; Choi, J.W. An Enzymatic Biosensor for Hydrogen Peroxide Based on CeO<sub>2</sub> Nanostucture Electrodeposited on ITO Surface. *Biosens. Bioelectron.* **2013**, *47*, 385–390. [CrossRef] [PubMed]

133. Ding, Y.; Wang, Y.; Li, B.; Lei, Y. Electrospun Hemoglobin Microbelts Based Biosensor for Sensitive Detection of Hydrogen Peroxide and Nitrite. *Biosens. Bioelectron.* **2010**, *25*, 2009–2015. [CrossRef]

134. Wu, H.; Fan, S.; Jin, X.; Zhang, H.; Chen, H.; Dai, Z.; Zou, X. Construction of a Zinc Porphyrin—Fullerene-Derivative Based Nonenzymatic Electrochemical Sensor for Sensitive Detection of Hydrogen Peroxide and Nitrite. *Anal. Chem.* **2014**, *86*, 6285–6290. [CrossRef]

135. Zhu, H.; Sigdel, A.; Zhang, S.; Su, D.; Xi, Z.; Li, Q.; Sun, S. Core/Shell Au/MnO Nanoparticles Prepared through Controlled Oxidation of AuMn as an Electrocatalyst for Sensitive H<sub>2</sub>O<sub>2</sub> Detection. *Angew. Chemie Int. Ed.* **2014**, *53*, 12508–12512. [CrossRef]

136. Xu, X.; Jiang, S.; Hu, Z.; Liu, S. Nitrogen-Doped Carbon Nanotubes: High Electrocatalytic Activity toward the Oxidation of Hydrogen Peroxide and Its Application for Biosensing. *ACS Nano* **2010**, *4*, 4292–4298. [CrossRef]

137. Cao, X.; Zeng, Z.; Shi, W.; Yep, P.; Yan, Q.; Zhang, H. Three-Dimensional Graphene Network Composites for Detection of Hydrogen Peroxide. *Small* **2013**, *9*, 1703–1707. [CrossRef]

138. Gó, A.; Park, S.R.; Ku, Y.; Sun, M.; Yeon, S.; Lee, J.K.; Lee, S.W.; Lee, M.H. Highly Sensitive Electrochemical Sensor for Diagnosis of Diabetic Ketoacidosis (DKA) by Measuring Ketone Bodies in Urine. *Sensors* **2021**, *21*, 4902. [CrossRef]

139. Verma, A.; Yadav, D.; Singh, A.; Gupta, M.; Thapa, K.B.; Yadav, B.C. Detection of Acetone via Exhaling Human Breath for Regular Monitoring of Diabetes by Low-Cost Sensing Device Based on Perovskite BaSnO<sub>3</sub> Nanorods. *Sensors Actuators B Chem.* **2022**, *361*, 131708. [CrossRef]

140. Khorsand, F.; Riahi, S.; Eynollahi Fard, S.; Kashanian, S.; Naemy, A.; Larjani, B.; Omidifar, K. Development of 3-hydroxybutyrate Dehydrogenase Enzyme Biosensor Based on Carbon Nanotube-modified Screen-printed Electrode. *IET Nanobiotechnol.* **2013**, *7*, 1–6. [CrossRef]

141. Khan, S.B.; Faisal, M.; Rahman, M.M.; Jamal, A. Low-Temperature Growth of ZnO Nanoparticles: Photocatalyst and Acetone Sensor. *Talanta* **2011**, *85*, 943–949. [CrossRef]

142. Kim, K.Y.; Schumacher, H.R.; Hunshe, E.; Wertheimer, A.I.; Kong, S.X. A Literature Review of the Epidemiology and Treatment of Acute Gout. *Clin. Ther.* **2003**, *25*, 1593–1617. [CrossRef]

143. Boulieu, R.; Bory, C.; Balkassat, P.; Gonnent, C. Hypoxanthine and Xanthine Levels Determined by High-Performance Liquid Chromatography in Plasma, Erythrocyte, and Urine Samples from Healthy Subjects: The Problem of Hypoxanthine Level Evolution as a Function of Time. *Anal. Biochem.* **1983**, *129*, 398–404. [CrossRef]

144. Villalonga, R.; Diez, P.; Eguilaz, M.; Martinez, P.; Pingarron, J.M. Supramolecular Immobilization of Xanthine Oxidase on Electropolymerized Matrix of Functionalized Hybrid Gold Nanoparticles/Single-Walled Carbon Nanotubes for the Preparation of Electrochemical Biosensors. *ACS Appl. Mater. Interfaces* **2012**, *4*, 4312–4319. [CrossRef] [PubMed]

145. Mu, S.; Shi, Q. Xanthine Biosensor Based on the Direct Oxidation of Xanthine at an Electrogeneratered Oligomer Film. *Biosens. Bioelectron.* **2013**, *47*, 429–435. [CrossRef]

146. Zhu, D.; Xin, J.; Li, X. Self-Assembly Encapsulation of Vanadium Tetrasulfide into Nitrogen Doped Biomass-Derived Porous Carbon as a High Performance Electrochemical Sensor for Xanthine Determination. *New J. Chem.* **2022**, *46*, 12773–12782. [CrossRef]

147. Caussé, E.; Pradelles, A.; Dirat, B.; Negre-Salvayre, A.; Salvayre, R.; Couderc, F. Simultaneous Determination of Allantoin, Hypoxanthine, Xanthine, and Uric Acid in Serum/Plasma by CE. *Electrophoresis* **2007**, *28*, 381–387. [CrossRef]

148. Saugstad, O.D. Hypoxanthine as an Indicator of Hypoxia: Its Role in Health and Disease through Free Radical Production. *Pediatr. Res.* **1998**, *23*, 143–150. [CrossRef]

149. Kalimuthu, P.; Leimkühler, S.; Bernhardt, P. V Low-Potential Amperometric Enzyme Biosensor for Xanthine and Hypoxanthine. *Anal. Chem.* **2012**, *84*, 10359–10365. [CrossRef]

150. Stefan, R.-I.; Bokretson, R.G.; van Staden, J.F.; Aboul-Enein, H.Y. Simultaneous Determination of Creatine and Creatinine Using Amperometric Biosensors. *Talanta* **2003**, *60*, 1223–1228. [CrossRef]
151. Kaçar, C.; Erden, P.E.; Peykardimci, S.; Kiliç, E. An FeO4-Nanoparticles-Based Amperometric Biosensor for Creatine Determination. Artif. Cells Nanomed. Biotechnol. 2013, 41, 2–7. [CrossRef] [PubMed]

152. Yadav, S.; Devi, R.; Kumar, A.; Pandur, C.S. Tri-Enzyme Functionalized ZnO-NPs/CHIT/c-MWCNT/PANI Composite Film for Amperometric Determination of Creatinine. Biosens. Bioelectron. 2011, 28, 64–70. [CrossRef] [PubMed]

153. Wen, T.; Zhu, W.; Xue, C.; Wu, J.; Han, Q.; Wang, X.; Zhou, X.; Jiang, H. Novel Electrochemical Sensing Platform Based on Magnetic Field-Induced Self-Assembly of FeO4@Polyaniline Nanoparticles for Clinical Detection of Creatinine. Biosens. Bioelectron. 2014, 56, 180–185. [CrossRef] [PubMed]

154. Wei, F.; Cheng, S.; Korin, Y.; Reed, E.F.; Gjertson, D.; Ho, C.; Gritsch, H.A.; Veale, J. Serum Creatinine Detection by a Conducting-Polymer-Based Electrochemical Sensor to Identify Allograft Dysfunction. Anal. Chem. 2012, 84, 7933–7937. [CrossRef]

155. Randviir, E.P.; Kampouris, D.K.; Banks, C.E. An Improved Electrochemical Creatinine Detection Method via a Jaffe-Based Procedure. Analyst 2013, 138, 6565–6572. [CrossRef]

156. Dong, Y.; Luo, X.; Liu, Y.; Yan, C.; Li, H.; Lv, J.; Yang, L.; Cui, Y. A Disposable Printed Amperometric Biosensor for Clinical Evaluation of Creatinine in Renal Function Detection. Talanta 2022, 248, 123592. [CrossRef]

157. Pedrozo-Penafiel, M.J.; Lopes, T.; Gutierrez-Beleno, L.M.; Da Costa, M.E.H.M.; Larrude, D.G.; Acuëlo, R.Q. Voltammetric Determination of Creatinine Using a Gold Electrode Modified with Nanot with Mixed with Graphene Quantum Dots-Copper. J. Electroanal. Chem. 2020, 878, 114561. [CrossRef]

158. Fava, E.L.; do Prado, T.M.; Garcia-Filho, A.; Silva, T.A.; Cincotto, F.H.; de Moraes, F.C.; Faria, R.C.; Fatibello-Filho, O. Non-Enzymatic Electrochemical Determination of Creatinine Using a Novel Screen-Printed Microcell. Talanta 2020, 207, 120277. [CrossRef]

159. Clark, J.A.; Coopersmith, C.M. Intestinal Crosstalk—a New Paradigm for Understanding the Gut as the “Motor” of Critical Illness. Shock 2007, 28, 384. [CrossRef]

160. Honda, K.; Takeda, K. Regulatory Mechanisms of Immune Responses to Intestinal Bacteria. Mucosal Immunol. 2009, 2, 187–196. [CrossRef]

161. Bischoff, S.C.; Krämer, S. Human Mast Cells, Bacteria, and Intestinal Immunity. Immunol. Rev. 2007, 217, 329–337. [CrossRef]

162. Tsuji, M.; Suzuki, K.; Kinoshita, K.; Fagarasan, S. Dynamic Interactions between Bacteria and Immune Cells Leading to Intestinal Iga Synthesis. In Proceedings of the Seminars in Immunology; Elsevier: Amsterdam, The Netherlands; 2008; Volume 20, pp. 59–66.

163. Müller, C.; Macpherson, A.J. Layers of Mutualism with Commensal Bacteria Protect Us from Intestinal Inflammation. Gut 2006, 55, 276–284. [CrossRef] [PubMed]

164. Guarner, F.; Malagelada, J.R. Gut Flora in Health and Disease. Lancet 2003, 361, 512–519. [CrossRef]

165. Witkowski, M.; Weeks, T.L.; Hazen, S.L. Gut Microbiota and Cardiovascular Disease. Circ. Res. 2020, 127, 553–570. [CrossRef] [PubMed]

166. Zhu, Y.; Jameson, E.; Crosatti, M.; Schäfer, H.; Rajakumar, K.; Bugg, T.D.H.; Chen, Y. Carnitine Metabolism to Trimethylamine by an Unusual Rieske-Type Oxygenase from Human Microbiota. Proc. Natl. Acad. Sci. USA 2014, 111, 4268–4273. [CrossRef]

167. Lever, M.; George, P.M.; Slow, S.; Bellamy, D.; Young, J.M.; Ho, M.; McIntyre, C.J.; Elmslie, J.L.; Atkinson, W.; Molyneux, S.L. Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. PLoS ONE 2014, 9, e114969.

168. Dambrova, M.; Latkovskis, G.; Kuka, J.; Strele, I.; Konrade, I.; Grinberg, S.; Hartmane, D.; Pugovics, O.; Erglis, A.; Liepins, E. Diabetes Is Associated with Higher Trimethylamine N-Oxide Plasma Levels. Exp. Clin. Endocrinol. Diabetes 2016, 124, 251–256. [CrossRef]

169. Suzuki, T.; Heaney, L.M.; Jones, D.J.L.; Ng, L.L. Trimethylamine N-Oxide and Risk Stratification after Acute Myocardial Infarction. Clin. Chem. 2017, 63, 420–428. [CrossRef]

170. Ottiger, M.; Nickler, M.; Steuer, C.; Odermatt, J.; Huber, A.; Christ-Crain, M.; Henzen, C.; Hoess, C.; Thomann, R.; Zimmerman, W. Trimethylamine-N-Oxide (TMAO) Predicts Fatal Outcomes in Community-Acquired Pneumonia Patients without Evident Coronary Artery Disease. Eur. J. Intern. Med. 2016, 36, 67–73. [CrossRef]

171. Chang, Y.C.; Chu, Y.H.; Wang, C.C.; Wang, C.H.; Tain, Y.L.; Yang, H.W. Rapid Detection of Gut Microbial Metabolite Trimethylamine N-Oxide for Chronic Kidney Disease Prevention. Biosens. Bioelectron. 2021, 11, 339. [CrossRef]

172. Waffo, A.F.T.; Mitrova, B.; Tiedemann, K.; Iobbi-Nivol, C.; Leimkühler, S.; Wollenberger, U. Electrochemical Trimethylamine N-Oxide Biosensor with Enzyme-Based Oxygen-Scavenging Membrane for Long-Term Operation under Ambient Air. Biosensors 2021, 11, 98. [CrossRef] [PubMed]

173. Yi, Y.; Liang, A.; Luo, L.; Zang, Y.; Zhao, H.; Luo, A. A Novel Real-Time TMAO Detection Method Based on Microbial Electrochemical Technology. Biosens. Bioelectron. 2022, 144, 108038. [CrossRef] [PubMed]

174. Beaumont, M.; Neyrinck, A.M.; Olivares, M.; Rodriguez, J.; de Rocca Serra, A.; Romain, M.; Bindels, L.B.; Cani, P.D.; Evenepoel, P.; Muccioli, G.G. The Gut Microbiota Metabolite Indole Alleviates Liver Inflammation in Mice. FASEB J. 2018, 32, 6681–6693. [CrossRef] [PubMed]

175. Skye, S.M.; Hazen, S.L. Microbial Modulation of a Uremic Toxin. Cell Host Microbe 2016, 20, 691–692. [CrossRef]

176. Zelante, T.; Puccetti, M.; Giovagnoli, S.; Romani, L. Regulation of Host Physiology and Immunity by Microbial Indole-3-Aldehyde. Curr. Opin. Immunol. 2021, 70, 27–32. [CrossRef] [PubMed]

177. Laparra, J.M.; Olivares, M.; Gallina, O.; Sanz, Y. Bifidobacterium Longum CECT 7347 Modulates Immune Responses in a Gliadin-Induced Enteropathy Animal Model. PLoS ONE 2012, 7, e30744. [CrossRef]
178. Yu, J.; Luo, Y.; Zhu, Z.; Zhou, Y.; Sun, L.; Gao, J.; Sun, J.; Wang, G.; Yao, X.; Li, W. A Tryptophan Metabolite of the Skin Microbiota Attenuates Inflammation in Patients with Atopic Dermatitis through the Aryl Hydrocarbon Receptor. *J. Allergy Clin. Immunol.* 2019, 143, 2108–2119. [CrossRef]

179. Rothhammer, V.; Mascanfroni, I.D.; Bunse, L.; Takenaka, M.C.; Kenison, J.E.; Mayo, L.; Chao, C.-C.; Patel, B.; Yan, R.; Blain, M. Type I Interferons and Microbial Metabolites of Tryptophan Modulate Astrocyte Activity and Central Nervous System Inflammation via the Aryl Hydrocarbon Receptor. *Nat. Med.* 2016, 22, 586–597. [CrossRef]

180. Wang, J.; Zhang, C.; Childers, W.S. A Biosensor for Detection of Indole Metabolites. *ACS Synth. Biol.* 2021, 10, 1605–1614. [CrossRef]

181. Filik, H.; Avan, A.A.; Aydar, S. Voltammetric Sensing of Uremic Toxin Indoxyl Sulfate Using High Performance Disposable Screen-Printed Graphene Electrode. *Curr. Pharm. Anal.* 2016, 12, 36–42. [CrossRef]

182. Bergerova, M.; Libansky, M.; Dejmkova, H. Determination of Indoxyl Sulphate on Carbon Film Composite Electrode and Carbon Paste Electrode. *Curr. Anal. Chem.* 2018, 14, 530–535. [CrossRef]

183. Diallo, A.K.; Tardy, J.; Zhang, Z.Q.; Bessuelle, F.; Jaffrezic-Renault, N.; Lemiti, M. Trimethylamine Biosensor Based on Pentacene Enzymatic Organic Field Effect Transistor. *Appl. Phys. Lett.* 2009, 94, 176. [CrossRef]

184. Bourigua, S.; El Ichi, S.; Korri-Youssoufi, H.; Maaref, A.; Dzyadevych, S.; Renault, N.J. Electrochemical Sensing of Trimethylamine Based on Polymeric–Flavin-Containing Monooxygenase (FMO3) and Ferrocene as Redox Probe for Evaluation of Fish Freshness. *Biosens. Bioelectron.* 2011, 28, 105–111. [CrossRef]

185. Mitsubayashi, K.; Kubotera, Y.; Hashimoto, Y.; Kon, T.; Nakakura, S.; Nishi, Y.; Endo, H. Trimethylamine Biosensor with Flavin-Containing Monooxygenase Type 3 (FMO3) for Fish-Freshness Analysis. *Sens. Actuators B Chem.* 2004, 103, 463–467. [CrossRef]

186. Kaushik, A.; Khan, R.; Solanki, P.; Gandhi, S.; Gohel, H.; Mishra, Y.K. From Nanosystems to a Biosensing Prototype for an Efficient Diagnostic: A Special Issue in Honor of Professor Bansi D. Malhotra. *Biosensors* 2021, 29, 359. [CrossRef]

187. Kujawskas, M.; Bhardwaj, S.K.; Mishra, Y.K.; Kaushik, A. Using graphene-based biosensors to detect dopamine for efficient parkinson’s disease diagnostics. *Biosensors* 2021, 11, 433. [CrossRef]

188. Manickam, P.; Mariappan, S.A.; Murugesan, S.M.; Hansda, S.; Kaushik, A.; Shinde, R.; Thipperudraswamy, S.P. Artificial Intelligence (AI) and Internet of Medical Things (IoMT) Assisted Biomedical Systems for Intelligent Healthcare. *Biosensors* 2022, 12, 562. [CrossRef]